EP1786384A1 - Use of at least one conjugated triene-containing fatty acid for preparing a medicine for treating inflammation - Google Patents

Use of at least one conjugated triene-containing fatty acid for preparing a medicine for treating inflammation

Info

Publication number
EP1786384A1
EP1786384A1 EP05790724A EP05790724A EP1786384A1 EP 1786384 A1 EP1786384 A1 EP 1786384A1 EP 05790724 A EP05790724 A EP 05790724A EP 05790724 A EP05790724 A EP 05790724A EP 1786384 A1 EP1786384 A1 EP 1786384A1
Authority
EP
European Patent Office
Prior art keywords
acid
weight
use according
group
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05790724A
Other languages
German (de)
French (fr)
Inventor
Antoine Piccirilli
Nathalie Piccardi
Philippe Msika
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Expanscience SA
Original Assignee
Laboratoires Expanscience SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Expanscience SA filed Critical Laboratoires Expanscience SA
Publication of EP1786384A1 publication Critical patent/EP1786384A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A61K36/428—Trichosanthes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Definitions

  • the subject of the invention is the use of at least one conjugated and optionally oxygenated fatty acid triene of synthetic and / or natural origin for the manufacture of a medicinal product intended for the treatment of inflammatory diseases and / or metabolic disorders. consecutive to inflammation.
  • ⁇ -linolenic acid The most common trienoic fatty acid found in plants is ⁇ -linolenic acid.
  • Several conjugated isomers of ⁇ -linolenic acid may be found in certain plant formulas and sometimes become major constituents of these vegetable oils. Catalysts of catalpa ovata, punicic acid of punica granatum, jacaric acid of jacaranda ninosisonia and calendulic acid of calendula officinalis, pomégranate (Punica granatum L.), catalpa (Catalpa ovata G .), balsam, ...
  • Conjugated fatty acid trienes such as ⁇ -linolenic acid or calendrical acid, have already been used in pharmaceutical compositions for treating and / or preventing cholesterol.
  • the inflammatory process is the set of reaction phenomena triggered, in a multicellular living organism, by the aggression of any pathogenic agent. It is an omni-tissue phenomenon taking place preferentially in the connective tissue which normally tends to limit and repair the effects of aggression. It ends with repair or healing of the lesion.
  • Inflammation can be caused by physical aggressions (such as hot, cold, ionizing radiation), chemical (caused by acidic or basic compounds, bacterial toxins). It may be the consequence of an infection related to the presence in the body of living pathogenic organisms such as bacteria, viruses, parasites or fungi. It can be caused by an immune reaction secondary to reintroduction into the body of an antigen. She can finally be the consequence of a tissue necrosis, itself secondary to many causes, for example an arterial occlusion.
  • the causes are multiple and represent the pathogens. They determine cellular or tissue lesions that will trigger inflammation: - physical causes (trauma, heat, cold, radiation, electric current);
  • the pathogen may be endogenous or exogenous and infectious causes (microorganisms) are only a small part of the causes of inflammation. Some causes determine lesions whose morphology is peculiar, hence the notion of specific inflammation. On the other hand, the same pathogen can cause different inflammatory reactions depending on the host hence the importance of factors related to the host (contributing factors or protective factors). The course of the inflammatory process evolves in three successive stages:
  • UV radiation reaches the skin, part of it is reflected from the surface. The rest of the radiation is scattered in the tissues just below the surface of the skin. A fraction of this radiation is absorbed by the living cells of the skin. Ultraviolet radiation absorbed by living cells damages sensitive substances that affect the normal development and appearance of the skin. Damage can lead to sunburn, accelerated aging of the skin and / or skin cancer.
  • Sunburn is the most known and immediate effect of ultraviolet radiation on the skin. It is an inflammation caused by increased blood flow under the skin. A brief, intense exposure can cause severe sunburn in people who are not used to the strong sun. There is evidence that this type of exposure, as well as long-term exposures can lead to the development of skin cancers. A repetition exposed to the ultraviolet radiation of the sun participates also to the aging process. The skin thins in places and loses its elasticity; imperfections, hyper-pigmentation and wrinkles also appear. These changes can occur after many years of exposure, but when they do occur, the damage is irreversible. If sun exposure continues for several years, damaged skin is at greater risk of developing one of the forms of skin cancer. Exposure to ultraviolet radiation increases the risk of developing these cancers.
  • Patent Application FR 2,630,648 describes a topical anti-inflammatory or anti-irritant composition comprising a zinc salt of one or more compounds selected from unsaturated fatty acids, polyunsaturated fatty acids and their cyclic derivatives, in which an approved excipient in a pharmacy.
  • This application also teaches that derivatives of certain unsaturated or polyunsaturated fatty acids or protenoic acid may exhibit anti-inflammatory activity; possible anti-inflammatory activity of polyunsaturated fatty acids is neither described nor suggested.
  • conjugated and optionally oxygenated fatty acid trienes of synthetic and / or natural origin can be used in the treatment of inflammation and / or to promote healing.
  • the subject of the present invention is therefore the use of a composition comprising at least one fatty acid chosen from the group consisting of alpha-eleostearic acid, catalpic acid, calendrical acid, jacaric acid, licanic acid and beta-eleostearic acid, for the manufacture of a medicament for the prevention and / or treatment of inflammatory diseases and / or metabolic disorders resulting from inflammation of the skin, mucous membranes and / or cartilage .
  • the composition may comprise alpha-linolenic acid, alone or in admixture with at least one conjugated fatty acid.
  • metabolic disorders consecutive to an inflammation of the skin, mucous membranes and / or cartilage is understood to mean all diseases related to a disturbance of the metabolism, said disturbance of the metabolism being induced. or following inflammation. These metabolic disorders therefore have in common inflammation of the skin, mucous membranes and / or cartilage and they correspond to the main or secondary effects of said inflammation.
  • the mucous membranes are advantageously chosen from the group consisting of oral, gingival, broncho-pulmonary, auricular, nasal, rectal or vaginal intestinal mucosa.
  • Alpha-eleostearic acid has the following formula:
  • the catalpic acid has the following formula:
  • the calendrical acid has the following formula:
  • the jacaric acid corresponds to the following formula:
  • Punic acid has the following formula:
  • the licanic acid has the following general formula:
  • Beta-eleostearic acid has the following formula:
  • the composition according to the invention comprises at least ⁇ -eleostearic acid and / or catalpic acid.
  • the conjugated fatty acid is chosen from the group consisting of alpha-eleostearic acid and catalpic acid, alone or as a mixture.
  • the inflammation may have a physical origin (heat, cold, ionizing radiation, infra-red radiation, solar radiation), mechanical (friction), chemical (contact with irritants or allergens such as a perfume or chemicals) or biological (microbe, mushroom).
  • the medicament is intended for the prevention and / or treatment of allergic and / or irritative reactions of the skin and / or mucous membranes.
  • the drug according to the invention is also suitable for promoting healing, in normal or pathological healing processes, such as ulcers and pressure ulcers.
  • the drug according to the invention is advantageously intended for the prevention and / or treatment of diseases selected from the group consisting of atopic eczema, inflammatory dermatoses such as psoriasis, irritative dermatitis, acne, seborrheic dermatitis, nummular eczema, dyshidrotic eczema,
  • diseases selected from the group consisting of atopic eczema, inflammatory dermatoses such as psoriasis, irritative dermatitis, acne, seborrheic dermatitis, nummular eczema, dyshidrotic eczema,
  • the drug is advantageously intended for the prevention and / or treatment of diseases selected from the group consisting of gingivitis and periodontitis.
  • the medicament is also advantageously intended for the prevention and / or treatment of diseases selected from the group consisting of vulvitis and vaginitis.
  • the drug is also advantageously intended for the prevention and / or treatment of diseases selected from the group consisting of arthritis and osteoarthritis.
  • Alpha linolenic acid has already been described as an anti-inflammatory agent (EP 0 226 468). The inventors have discovered that it can also be used for the manufacture of a medicament for the prevention and / or treatment of inflammatory diseases and / or metabolic disorders resulting from inflammation of the body. skin, mucous membranes and / or cartilage.
  • alpha-linolenic acid can be used for the manufacture of a medicament for treatment:
  • atopic eczema inflammatory dermatoses such as psoriasis, irritative dermatitis, acne, seborrheic dermatitis, nummular eczema, dyshidrotic eczema, Pytiriasis alba, eczema crackling, nutritional eczema, urticaria, parasitic dermatoses, viral dermatoses, fungal or bacterial dermatoses, intertrigo, inflammatory topical vascularization disorders, foot ulcer and / or insect bites; - gingivitis and periodontitis;
  • the present invention also relates to the use of a composition comprising at least one fatty acid selected from the group consisting of alpha-eleostearic acid, catalpic acid, calendrical acid, jacaric acid, licanic acid and beta-eleostearic acid, for the cosmetic treatment of skins and / or mucous membranes that are sensitive, irritated, intolerant, have an allergic tendency, are aged, have a skin barrier disorder, have skin rashes or have an immunological imbalance non-pathological related to intrinsic aging, extrinsic or hormonal.
  • a composition comprising at least one fatty acid selected from the group consisting of alpha-eleostearic acid, catalpic acid, calendrical acid, jacaric acid, licanic acid and beta-eleostearic acid
  • Alpha-linolenic acid may also be used in a cosmetic composition for the cosmetic treatment of skins and / or mucous membranes that are sensitive, irritated, intolerant, have an allergic tendency, are elderly, have a cutaneous barrier disorder, have cutaneous redness or exhibit a non-pathological immunological imbalance related to intrinsic, extrinsic or hormonal aging.
  • the cosmetic treatment may consist of the application or the ingestion of a cosmetic or nutraceutical composition respectively.
  • the subject of the present invention is also the use of a composition comprising at least one conjugated fatty acid chosen from the group consisting of alpha-eleostearic acid, catalpic acid, calendrical acid, jacaric acid, licanic acid and beta-eleostearic acid, for the cosmetic treatment of cellulite.
  • a composition comprising at least one conjugated fatty acid chosen from the group consisting of alpha-eleostearic acid, catalpic acid, calendrical acid, jacaric acid, licanic acid and beta-eleostearic acid, for the cosmetic treatment of cellulite.
  • Alpha linolenic acid can also be used in a cosmetic composition for the cosmetic treatment of cellulite.
  • Cellulite is an inflammation of the cell tissue located mainly under the skin in predisposed areas (thighs, hips, buttocks).
  • Cellulitis is an inflammation of the subcutaneous cell tissue, and is manifested by induration of the affected area. This phenomenon may be due to insufficient flow of the local microcirculation which alters the exchanges between the blood and the cellular tissues, which leads to an excessive fixation of water, fat, and an accumulation of waste at the level of the cells.
  • the composition comprising at least one conjugated fatty acid selected from the group consisting of alpha-eleostearic acid, catalpic acid, calendrical acid, jacaric acid, licanic acid and Beta-eleostearic acid can be formulated in the form of various preparations suitable for topical, oral, rectal, vaginal, nasal, atrial, bronchial, or parenteral administration.
  • the composition according to the invention is advantageously formulated for topical or oral administration.
  • the composition may comprise alpha-linolenic acid, alone or in admixture with at least one conjugated fatty acid.
  • the various formulations may include creams, ointments, lotions, oils, patches, sprays or any other products for external application.
  • the composition to be administered topically advantageously comprises 0.001 to 50% by weight, still more preferably 0.5 to 20% by weight, of at least one conjugated fatty acid selected from the group consisting of ⁇ -eleostearic acid. , catalpic acid, calendrical acid, jacaric acid, licanic acid and ⁇ -eleostearic acid, relative to the total weight of said composition.
  • the composition administered topically comprises 0.001 to 50% by weight, advantageously 0.5 to 20% by weight, still more advantageously 1 to 10% by weight, of alpha-eleostearic acid and 0.001 to
  • the composition administered topically advantageously comprises 0.001 to 50% by weight, advantageously 0.5 to 20% by weight, still more advantageously 1 to 10% by weight, of alpha-eleostearic acid. , relative to the total weight of said composition.
  • the drug or the cosmetic composition may be administered in unit or multidose administration forms in admixture with suitable pharmaceutical or cosmetic carriers known to those skilled in the art.
  • suitable unit dosage forms include, optionally, scored tablets, capsules, powders, granules and oral solutions or suspensions.
  • Suitable multidose forms of administration include oral drops, emulsions and syrups.
  • the composition may be formulated as a dietary supplement.
  • the conjugated fatty acid (s) according to the invention are mixed with a pharmaceutically or cosmetically acceptable vehicle such as, in particular, gelatin, talc, starch, lactose, magnesium stearate, gum arabic or their analogues.
  • a pharmaceutically or cosmetically acceptable vehicle such as, in particular, gelatin, talc, starch, lactose, magnesium stearate, gum arabic or their analogues.
  • the tablets may optionally be coated, that is to say covered with several layers of various substances such as sucrose, to facilitate the setting or storage.
  • the tablets may still have a more or less complex formulation intended to modify the rate of release of the active ingredient.
  • the release of the active ingredient of said tablet can be accelerated, slowed down or delayed depending on the desired absorption.
  • a preparation in capsules is obtained by mixing the conjugated fatty acid (s) according to the invention with a diluent.
  • a syrup preparation may contain the conjugated fatty acid (s) according to the invention together with a sweetener, preferably a sweetener, a flavoring agent and a suitable dye.
  • the water-dispersible powders or granules may comprise the conjugated fatty acid (s) according to the invention in admixture with dispersants or wetting agents, suspending agents, such as polyvinypyrrolidone, or sweeteners or preservatives. taste correctors.
  • the composition administered orally advantageously comprises 0.001% to
  • the composition administered orally comprises 0.001 to 100% by weight, advantageously 1 to 50% by weight. weight, alpha-eleostearic acid, and 0.001 to 100% by weight, preferably 1 to 50% by weight, of catalpic acid, relative to the total weight of said composition.
  • the composition administered orally comprises 0.001 to 100% by weight, advantageously 1 to 50% by weight, of alpha-eleostearic acid, relative to the total weight of said composition.
  • composition according to the invention when the composition according to the invention is formulated in the form of a dietary supplement, said dietary supplement may comprise up to 100% by weight of active ingredients according to the invention, ie particular fatty acids defined in the present invention. invention.
  • the amount of active ingredients that will comprise the composition according to the invention depends primarily on the mode of administration and the chosen dosage form.
  • the modes of administration, the dosages and the optimum dosage forms of the compositions according to the invention can be determined according to the criteria generally taken into account in the establishment of a pharmaceutical treatment, in particular a dermatological treatment, or a cosmetic treatment adapted to a patient such as eg age or body weight of patient, severity of general condition, tolerance to treatment, the side effects noted, the type of skin.
  • a pharmaceutical treatment in particular a dermatological treatment, or a cosmetic treatment adapted to a patient such as eg age or body weight of patient, severity of general condition, tolerance to treatment, the side effects noted, the type of skin.
  • the drug and / or the active compounds according to the invention may further comprise at least one pharmaceutically acceptable excipient, in particular dermatologically acceptable, or cosmetically acceptable.
  • an excipient suitable for topical external or oral administration is used.
  • the medicament or the cosmetic composition according to the present invention may further comprise at least one adjuvant which is pharmaceutically or cosmetically known to those skilled in the art, chosen from thickeners, preservatives, perfumes, dyes, chemical or mineral filters, moisturizers, thermal waters, etc.
  • the medicament according to the invention is intended for the treatment and / or prevention of diseases that may affect humans and / or animals, especially mammals.
  • the medicament or the cosmetic composition according to the invention may further comprise, in combination, advantageously with a synergistic effect, at least one compound chosen from the group consisting of emollients, moisturizing active agents, activators of keratin synthesis, keratoregulators, keratolytics, skin barrier restructuring agents (activators of cutaneous lipid synthesis), activators of differentiation of keratinocytes (retinoids or retinoids like, calcidone®, calcium), modulators of the differentiation of the epidermis, agents strengthening the epidermal dermal junction, antibiotics, anti-bacterial agents, antifungal compounds, anti-viral agents, stimulants of innate immunity (natural antibiotic peptides) or acquired, the sebo-regulators , such as the 5-alpha reductase inhibitors, in particular the 5-alpha Avocuta® active agent marketed by Laborato Expanscience or the salts of zinc and sabal (Sabalinae of the subfamily Coryphoideae), immunomodul
  • the composition comprises, in combination, advantageously with a synergistic effect, active principles chosen from the group consisting of anti-inflammatory agents.
  • the activators of keratin synthesis that can be used in combination, advantageously with a synergistic effect, with the conjugated fatty acids are advantageously retinoids or retinoids like, the lupine peptides marketed by Silab, key proteins of the stratum corneum. or granulosum (keratins).
  • the antibiotics that can be used in combination, advantageously with a synergistic effect, with the conjugated fatty acids are advantageously fucidic acid, penicillin, tetracyclines, pristinamycin, erythromycin, clindamycin, mupirocine, minocycline, doxycycline.
  • the anti-viral agents that can be used in combination with the conjugated fatty acids are advantageously acyclovir and valacyclovir.
  • anti-irritant agents that can be used in the context of the present invention in combination, advantageously with a synergistic effect, with the conjugated fatty acids are advantageously glycine, sugars and / or peptides of lupine, sugars and / or peptides described in patent applications FR0404635 and
  • the soothing agents that can be used in combination, advantageously with a synergistic effect, with the conjugated fatty acids are advantageously alpha bisabolol, licorice derivatives, enoxolone (3-beta-hydroxy-1-oxo-olean acid). 12-en-30-oic, CAS No. 471-53-4).
  • the kératorégulados that can be used in combination with the conjugated fatty acids are advantageously alpha hydroxy acids and their derivatives.
  • the keratolytics that may especially be used in combination with the conjugated fatty acids are salicylic acid and its derivatives: lipohydroxyacids.
  • the antioxidant agents that may be used in combination with the conjugated fatty acids are advantageously vitamins (C, E), trace elements (copper, zinc, selenium) and anti-oxidant enzymes.
  • the growth factors that can advantageously be used in combination with a synergistic effect with the conjugated fatty acids are advantageously becaplermine and TGF-beta (Transforming Growth Factor beta).
  • the healing agents which can advantageously be used in combination with a synergistic effect, with the conjugated fatty acids are advantageously vitamin A, panthenol, avocadofurane®, zinc oxide, magnesium, silicon, acid madécassique or Asian, the polysaccharides of all origins and in particular of marine thermal origin or the derivatives of pearl oyster.
  • the medicaments that can be used in the context of the present invention, in combination, advantageously with a synergistic effect, with the conjugated fatty acids are advantageously the drugs, suitable for administration for the topical or oral route, for the prevention and / or the treatment of atopy (corticosteroids, emollients, immunomodulators), acne (antibiotics, benzoyl peroxide, topical and oral retinoids, azelaic acid, vitamin PP, zinc, cyclins), eczema (immunomodulators, emollients, fish oil, borage, meadow and pro - biotic) or psoriasis (corticosteroids, calcipotriol, calcitriol, tazarotene, cade oil, acitretin, PUVA therapy, vitamin D derivatives).
  • the drug may also include antibiotic peptide stimulants such as avocado sugars and avocado peptides.
  • anti-inflammatory agents that can be used in combination, advantageously with a synergistic effect, with the conjugated fatty acids are advantageously steroidal anti-inflammatory agents (AIS), such as steroids, or non-steroids (NSAIDs) and anti-inflammatory agents.
  • AIS steroidal anti-inflammatory agents
  • NSAIDs non-steroids
  • Cox 2 celecoxib
  • the restructuring agents of the cutaneous barrier which make it possible to stimulate the synthesis of the key lipids of the epidermis, and which can be used in combination, advantageously with a synergistic effect, with the conjugated fatty acids are advantageously concentrates of sunflower, even more advantageously concentrates.
  • linoleic sunflower seeds such as the active ingredient marketed by Laboratoires Expanscience, Soline® (see international application WO 01/21150), vegetable oil unsaponifiables, such as Avocadofurane® (see international application WO 01 / 21150), PPAR agonists alpha, beta, gamma and delta (rosiglitazone, pioglitazone).
  • the RXR and RAR agonists vitamin D receptors.
  • the antifungal compounds that can be used in combination with the conjugated fatty acids are advantageously Peconazole, ketoconazole and climbazole. It is also possible to use reducing agents such as ichthyol in combination.
  • the antiseptic preservatives that can be used in combination, advantageously with a synergistic effect, with the conjugated fatty acids may be triclosan, chlorhexidine or quaternary ammoniums.
  • the immunomodulators which can be used in combination, advantageously with a synergistic effect, with the conjugated fatty acids are advantageously tacrolimus, pimecrolimus and oxazolines.
  • oxazolines which can be used in the context of the present invention are advantageously oxazolines chosen from the group consisting of 2-undecyl-4-hydroxymethyl-4-methyl-1,3-oxazoline and 2-undecyl-4,4-dimethylamine. dimethyl-1,3-oxazoline, the
  • the compounds containing vegetable oil unsaponifiables that can be used in combination, advantageously with a synergistic effect, with the conjugated fatty acids are advantageously chosen from the group consisting of avocado furan lipids, avocado and soya unsaponifiables. , lupine oil concentrates, sunflower oil concentrates and mixtures thereof.
  • the furanic lipids of avocado that can be used in the context of the present invention are advantageously natural 2-alkyl furans, in particular the active Avocadofurane® sold by Laboratoires Expanscience, obtainable by the process described in international application WO 01 / 21605.
  • the avocado and soya unsaponifiables which can be used in combination with the conjugated fatty acids are advantageously a mixture of unsaponifiables of furanic avocado and unsaponifiable soya, in a respective ratio of approximately 1 / 3-2 / 3 .
  • the unsaponifiable avocado and soya are even more advantageously the product Piasclédine®, marketed by Laboratoires Expanscience.
  • the lupine oil concentrates that may be used are advantageously concentrates obtained by molecular distillation of lupine oil, advantageously sweet white lupine oil, such as those described in the international application WO 98/47479. They advantageously contain about 60% by weight of unsaponifiables.
  • the sunflower oil concentrates that can be used are advantageously linoleic sunflower concentrates, such as the active ingredient marketed by Laboratoires Expanscience, Soline® (see the international application WO
  • the source of conjugated fatty acid is a lipid extract of at least one plant selected from the group consisting of plants of the family Cucurbitaceae, Punicaceae, Bignoniaceae, Euphorbiaceae, Composites (Asteraceae), Balsaminaceae, Rosaceae, Chrysobalanaceae, Ricinocarpus and Chilopsis.
  • the conjugated fatty acid source is a lipid extract of at least one plant selected from the group consisting of green, white, pearly and wild Mormordica, Catalpa, Peerites, Euphorbia, Parinarium, Licania, Parinarium, Calendula, Punica, Pomegranate, Chinese Wood, Balsam, Trichosanthes and Centrarus, Jacaranda.
  • the source of alpha-eleostearic acid is advantageously virgin and / or refined oils of at least one plant selected from the group consisting of Momordica charantia, Aleuritippo montana and Aleuritippo fordii, Parinarium montanum, Parinarium excelsum , Parinarium macrophyllum, Parinarium holstii, Licania rigida and Ricinocarpus bowmanii.
  • the source of catalpic acid is advantageously virgin and / or refined oils of at least one plant selected from the group consisting of Catalpa ovata, Catalpa hignoniodes and Chilopsis linearis.
  • the source of calandic acid is advantageously a virgin and purified oil of Calendula officinalis.
  • the source of punicic acid is advantageously virgin and / or refined oils of at least one plant selected from the group consisting of Punica granatum, Trichosanthes nervifolia and Momordica balsamina.
  • the source of beta-eleostearic acid is advantageously a virgin and purified oil of Centratus ruber.
  • the source of licanic acid is advantageously Oitica, Licania or Parinarium oil.
  • the virgin and / or refined oils mentioned above do not contain any trace of detectable protein.
  • the source of alpha-eleostearic acid and catalpic acid is more particularly a lipid extract of Mormordica seeds, advantageously seeds of Momordica charantia.
  • the composition according to the invention administered topically comprises 0.001% to 50% by weight of a lipid extract of momordic seeds, advantageously 0.001% to 50% by weight, even more advantageously 2 at 20% by weight, of a lipid extract of Momordica charantia seeds, relative to the total weight of the composition.
  • the composition according to the invention administered orally comprises 0.001% to 100% by weight of a lipid extract of momordic seeds, advantageously 0.001% to 100% by weight of lipid extract seed of Momordica charantia, more advantageously 1 to 50% by weight of a lipid extract of Momordica charantia seeds, relative to the total weight of the composition.
  • the lipid extract of Momordica charantia seeds advantageously comprises at least 20% by weight of alpha-eleostearic acid and of catalpic acid, advantageously at least 40% by weight of alpha-eleostearic acid and of catalpic acid, and even more advantageously about 45% by weight of alpha-eleostearic acid and catalpic acid.
  • the mixture of alpha-eleostearic acid and catalpic acid advantageously comprises at least 50% by weight of alpha-eleostearic acid, advantageously at least 90% by weight of alpha-eleostearic acid, still more advantageously at least 98% by weight. weight of alpha-eleostearic acid.
  • the Margoze of the genus Momordica charantia is a tropical cucurbit that comes from India but is also grown on the island of Reunion. It is an annual herb, which can give lianas 2 meters long, and whose oblong fruits of green color contain flat seeds. The lipid content of these seeds is about 30% by weight.
  • the lipid extract of Momordica charantia is obtainable by a process consisting in extracting the total lipids from the seeds of Momordica charantia previously dried and crushed, using a solvent of the oils, then evaporating said solvent or according to the process of extracting the lipids from the seeds of Momordica charantia by mechanical pressure of the seeds cold.
  • the oil of the seeds of Momordica charantia can be obtained according to the process of extracting the total lipids from the seeds of cucurbitaceae previously dried and crushed, with the aid of a solvent of the oils, then to evaporate the solvent.
  • the seeds of Momordica charantia according to the present invention are milled for example using a roller mill or hammers.
  • the oil solvent used to extract the total lipids from the oil-forming seeds is a conventional organic lipid extraction solvent.
  • the solvent is advantageously chosen from the group consisting of aliphatic alkanes, aromatic alkanes, aliphatic alcohols and their halogenated derivatives. Even more advantageously according to the present invention, the organic solvent is hexane.
  • the extraction of the total lipids from the seeds of Momordica charantia is advantageously carried out by a Soxhlet extraction which is a technology well known to those skilled in the art.
  • the organic solvent is evaporated, preferably by evaporation under vacuum.
  • the seed oil of Momordica charantia can be obtained by the process of extracting the lipids from cucurbitaceae seeds by mechanical pressure of the cold seeds, advantageously with using a continuous screw press, to conduct, after filtration, virgin oils of first pressure.
  • the lipid extracts of the other plants according to the present invention are capable of being obtained by methods similar to the processes described above.
  • the oils of the plant (s) according to the present invention can be used raw or refined.
  • refining is understood to mean the unitary lipid purification operations of plant origin well known to those skilled in the art, among which may be mentioned in particular chemical neutralization, degumming, decolourisation, deodorization. and frigmentation.
  • the oils extracted from Momordica charantia seeds have the additional advantage of being cosmetically acceptable, non-aggressive to the skin, non-toxic and hypoallergenic.
  • Example 1 Cosmetic Formulations Based on a Momordica Charantia Extract
  • QSP Sufficient Quantity For
  • QS Sufficient quantity (Anti-acne cream n ° 2
  • QSP Sufficient Quantity For
  • QS Sufficient quantity
  • Example 4 Study of the effect of an extract of Momordica charantia in a model of mechanically induced cutaneous inflammation (shaving) in the wild Balb / c mouse. Protocol
  • mice Female Balb / c mice aged 6 weeks. Each group of mice consists of 8 mice. At OJ, the mice are shaved on their backs
  • Momordica charantia is applied at a dose of 2%, twice daily. At day 4, ie after 2 days of topical application of Momordica charantia extract, skin biopsies are performed. Histological analysis is performed by staining the haematoxylin / eosin sections.
  • the extract of Momordica charantia used includes by weight:
  • the vehicle-treated group (acetone / olive oil) has a skin thickness at J4, statistically higher than that of the group treated with 2% Momordica charantia extract for 2 days ( Figure 1).
  • an extract of Momordica charantia has anti-inflammatory properties in a mechanically induced skin inflammation model in mice.
  • FIG. 1 represents, on the ordinate, the thickness of the skin, in microns at day 4, measured in each of the treated groups (vehicle: acetone / olive oil or Momordica charantia extract).
  • Example 5 Study of the effect of an extract of Momordica charantia, applied topically at the dose of 2% in the Balb / c wild-type mouse, on the proliferation of keratinocytes. Protocol The study was performed on female Balb / c mice aged 6 weeks.
  • mice Each group of mice consists of 8 mice. At OJ, the mice are shaved on the back (surface of about 2 cm 2 ). At J2, a first group of mice is used to obtain the basic values.
  • Momordica charantia extract is applied at 2% for 30 days, twice daily.
  • the extract of Momordica charantia used is the same as that of Example 4.
  • FIG. 2 represents the percentage of Ki-67 positive cells relative to the total number of cells measured at J30 in each of the treated groups (vehicle: acetone / olive oil or Momordica charantia extract).
  • an extract of Momordica charantia causes an increase in the proliferation of keratinocytes in vivo in the mouse.
  • Momordica charantia extract has healing and eutrophic properties.
  • the said eutrophic properties are advantageous especially in the context of cutaneous pathologies characterized by a skin barrier disorder.
  • the extract of Momordica charantia used is the same as that of Example 4. Culture conditions
  • Momordica charantia extract does not induce any interference with radiolabeling.
  • the reference molecule, cerulin (FAS inhibitor, Fatty Acid Synthase) tested at 10 ⁇ M inhibits the incorporation of acetate (75% inhibition / control). This result validates the test.
  • the extract of Momordica charantia tested at 2 and 20 ppm significantly reduces the incorporation of acetate into the lipids (respectively 25 and 30% of the control).
  • Momordica charantia extract shows a significant inhibitory activity of lipid synthesis.
  • the extract of Momordica charantia is therefore capable of inhibiting lipogenesis in human adipocytes in culture. This experience shows quite unexpectedly the interest of the product in the management of cellulite.
  • FIG. 3 attached illustrates the effect of Momordica charantia extract on the incorporation of radiolabelled acetate into adipocyte lipids. The results are significant (p ⁇ 0.01).

Abstract

The invention concerns the use of at least one conjugated triene-containing fatty acid for preparing a medicine for treating inflammation selected among the group consisting of alpha-eleostearic acid, catalpic acid, calendic acid, jacaric acid, licanic acid and beta-eleostearic acid for making a medicine for treating inflammatory diseases and/or metabolic disorders following an inflammation. The inflammatory diseases and/or metabolic disorders following an inflammation may be skin cancers, sun burn, benign summer light eruption, allergic and/or irritative reactions, gingivitis and periodontitis, vulvitis and vaginitis or arthritis and arthrosis. The medicine also enables healing to be promoted. Said fatty acid conjugates can also be used in the cosmetic treatment of cellulitis.

Description

Utilisation d'au moins un triène d'acide gras conjugué pour Ia préparation d'un médicament destiné au traitement de l'inflammation. Use of at least one conjugated fatty acid triene for the preparation of a medicament for the treatment of inflammation.
L'invention a pour objet l'utilisation d'au moins un triène d'acide gras conjugué et éventuellement oxygéné d'origine synthétique et/ou naturelle pour la fabrication d'un médicament destiné au traitement des maladies inflammatoires et/ou des désordres métaboliques consécutifs à une inflammation.The subject of the invention is the use of at least one conjugated and optionally oxygenated fatty acid triene of synthetic and / or natural origin for the manufacture of a medicinal product intended for the treatment of inflammatory diseases and / or metabolic disorders. consecutive to inflammation.
L'acide gras triénoïque le plus commun que l'on retrouve dans les plantes est l'acide α-linolénique. Plusieurs isomères conjugués de l'acide α-linolénique peuvent se trouver dans certaines formules de plantes et deviennent parfois des constituants majoritaires de ces huiles végétales. On peut notamment citer les acides catalpiques de catalpa ovata, l'acide punicique de punica granatum, l'acide jacarique de jacaranda ninosisonia et l'acide calendique de calendula officinalis, le pomégranate (Punica granatum L.), le catalpa (Catalpa ovata G.), le balsam, ...The most common trienoic fatty acid found in plants is α-linolenic acid. Several conjugated isomers of α-linolenic acid may be found in certain plant formulas and sometimes become major constituents of these vegetable oils. Catalysts of catalpa ovata, punicic acid of punica granatum, jacaric acid of jacaranda ninosisonia and calendulic acid of calendula officinalis, pomégranate (Punica granatum L.), catalpa (Catalpa ovata G .), balsam, ...
Des triènes d'acides gras conjugués, tels que l'acide α-linolénique ou l'acide calendique, ont déjà été utilisés dans des compositions pharmaceutiques destinées à traiter et/ou prévenir le cholestérol.Conjugated fatty acid trienes, such as α-linolenic acid or calendrical acid, have already been used in pharmaceutical compositions for treating and / or preventing cholesterol.
Le processus inflammatoire est l'ensemble des phénomènes réactionnels déclenchés, dans un organisme vivant pluricellulaire, par l'agression d'un agent pathogène quel qu'il soit. C'est un phénomène omni-tissulaire se déroulant de façon préférentielle dans le tissu conjonctif qui normalement tend à limiter et à réparer les effets de l'agression. Il prend fin avec la réparation ou la cicatrisation de la lésion.The inflammatory process is the set of reaction phenomena triggered, in a multicellular living organism, by the aggression of any pathogenic agent. It is an omni-tissue phenomenon taking place preferentially in the connective tissue which normally tends to limit and repair the effects of aggression. It ends with repair or healing of the lesion.
L'inflammation peut être causée par des agressions physiques (comme le chaud, le froid, les radiations ionisantes), chimiques (occasionnées par des composés acides ou basiques, des toxines bactériennes). Elle peut être la conséquence d'une infection en rapport avec la présence dans l'organisme d'organismes vivants pathogènes tels que bactéries, virus, parasites ou champignons. Elle peut être provoquée par une réaction immunitaire secondaire à la réintroduction dans l'organisme d'un antigène. Elle peut enfin être la conséquence d'une nécrose tissulaire, elle-même secondaire à de nombreuses causes, par exemple une occlusion artérielle.Inflammation can be caused by physical aggressions (such as hot, cold, ionizing radiation), chemical (caused by acidic or basic compounds, bacterial toxins). It may be the consequence of an infection related to the presence in the body of living pathogenic organisms such as bacteria, viruses, parasites or fungi. It can be caused by an immune reaction secondary to reintroduction into the body of an antigen. She can finally be the consequence of a tissue necrosis, itself secondary to many causes, for example an arterial occlusion.
Les causes sont multiples et représentent les agents pathogènes. Elles déterminent des lésions cellulaires ou tissulaires qui vont déclencher l'inflammation : - causes physiques (traumatisme, chaleur, froid, rayonnement, courant électrique) ;The causes are multiple and represent the pathogens. They determine cellular or tissue lesions that will trigger inflammation: - physical causes (trauma, heat, cold, radiation, electric current);
- causes trophiques par défaut de vascularisation ;- trophic causes by default of vascularization;
- causes chimiques (acides, bases, corps "étrangers" exogènes ou endogènes) ;- chemical causes (acids, bases, exogenous or endogenous "foreign" bodies);
- causes biologiques (germes, bactéries, virus, parasites, champignons) ;- biological causes (germs, bacteria, viruses, parasites, fungi);
- conflit immunitaire. Dans l'inflammation, l'agent pathogène peut être endogène ou exogène et les causes infectieuses (micro-organismes) ne constituent qu'une petite partie des causes de l'inflammation. Certaines causes déterminent des lésions dont la morphologie est particulière d'où la notion d'inflammation spécifique. D'autre part, un même agent pathogène peut entraîner des réactions inflammatoires différentes selon l'hôte d'où l'importance des facteurs liés à l'hôte (facteurs favorisants ou facteurs protecteurs). Le déroulement du processus inflammatoire évolue en trois stades successifs:- immune conflict. In inflammation, the pathogen may be endogenous or exogenous and infectious causes (microorganisms) are only a small part of the causes of inflammation. Some causes determine lesions whose morphology is peculiar, hence the notion of specific inflammation. On the other hand, the same pathogen can cause different inflammatory reactions depending on the host hence the importance of factors related to the host (contributing factors or protective factors). The course of the inflammatory process evolves in three successive stages:
- un stade caractérisé par les réactions vasculo-sanguines ;a stage characterized by vasculo-sanguine reactions;
- un stade caractérisé par les réactions cellulaires (phase productive) ;a stage characterized by cellular reactions (productive phase);
- un stade de cicatrisation ou de regénération. Lorsque le rayonnement ultraviolet atteint la peau, une partie en est réfléchie de la surface. Le reste du rayonnement est diffusé dans les tissus juste sous la surface de la peau. Une fraction de ce rayonnement est absorbée par les cellules vivantes de la peau. Le rayonnement ultraviolet absorbé par les cellules vivantes endommage les substances' sensibles qui influent sur le développement et l'aspect normaux de la peau. Les dommages peuvent entraîner des coups de soleil, une accélération du vieillissement de la peau et/ou le cancer de la peau.- a stage of healing or regeneration. When ultraviolet radiation reaches the skin, part of it is reflected from the surface. The rest of the radiation is scattered in the tissues just below the surface of the skin. A fraction of this radiation is absorbed by the living cells of the skin. Ultraviolet radiation absorbed by living cells damages sensitive substances that affect the normal development and appearance of the skin. Damage can lead to sunburn, accelerated aging of the skin and / or skin cancer.
Le coup de soleil est l'effet le plus connu et immédiat du rayonnement ultraviolet sur la peau. Il s'agit d'une inflammation causée par un accroissement du débit sanguin sous la peau. Une exposition intense brève peut causer un grave coup de soleil chez les personnes qui ne sont pas habituées au soleil fort. Il est prouvé que ce type d'exposition, de même que les expositions à long terme peuvent entraîner l'apparition de cancers cutanés. Une répétition exposée au rayonnement ultraviolet du soleil participe également au processus de vieillissement. La peau s'amincit par endroits et perd de son élasticité; des imperfections, une hyper-pigmentation et des rides apparaissent également. Ces changements peuvent se produire après de nombreuses années d'exposition mais, lorsqu'ils surviennent, les dommages sont irréversibles. Si l'exposition au soleil se poursuit pendant plusieurs années, la peau endommagée court un plus grand risque de développer une des formes de cancer de la peau. L'exposition au rayonnement ultraviolet accroît les risques de développement de ces cancers. Il semble que l'exposition discontinue (occasionnelle) et que l'exposition pendant l'enfance et l'adolescence soient des prédicteurs probablement importants du carcinome basocellulaire et du mélanome malin cutané. Des niveaux élevés d'exposition chronique, comme dans le cas des personnes qui travaillent à l'extérieur, sont plus souvent associés à l'épithélomia spinocellulaire.Sunburn is the most known and immediate effect of ultraviolet radiation on the skin. It is an inflammation caused by increased blood flow under the skin. A brief, intense exposure can cause severe sunburn in people who are not used to the strong sun. There is evidence that this type of exposure, as well as long-term exposures can lead to the development of skin cancers. A repetition exposed to the ultraviolet radiation of the sun participates also to the aging process. The skin thins in places and loses its elasticity; imperfections, hyper-pigmentation and wrinkles also appear. These changes can occur after many years of exposure, but when they do occur, the damage is irreversible. If sun exposure continues for several years, damaged skin is at greater risk of developing one of the forms of skin cancer. Exposure to ultraviolet radiation increases the risk of developing these cancers. It appears that intermittent (occasional) exposure and exposure during childhood and adolescence are probably important predictors of basal cell carcinoma and cutaneous malignant melanoma. High levels of chronic exposure, as in the case of people working outdoors, are more often associated with squamous cell epitheloma.
Trois types différents de cancer de la peau sont liés à l'exposition au soleil: Carcinome basocellulaire; Épithélioma spinocellulaire; et Mélanome malin. La demande de brevet FR 2 630 648 décrit une composition topique anti- inflammatoire ou anti-irritante comprenant un sel de zinc d'un ou de plusieurs composés choisis parmi les acides gras insaturés, les acides gras poly-insaturés et leurs dérivés cycliques, dans un excipient agréé en pharmacie. Cette demande enseigne également que les dérivés de certains acides gras insaturés ou poly-insaturé ou l'acide proténoïque peuvent présenter une activité anti-inflammatoire ; une éventuelle activité anti-inflammatoire des acides gras poly-insaturés n'est ni décrite ni suggérée.Three different types of skin cancer are related to sun exposure: Basal cell carcinoma; Squamous cell epithelioma; and malignant melanoma. Patent Application FR 2,630,648 describes a topical anti-inflammatory or anti-irritant composition comprising a zinc salt of one or more compounds selected from unsaturated fatty acids, polyunsaturated fatty acids and their cyclic derivatives, in which an approved excipient in a pharmacy. This application also teaches that derivatives of certain unsaturated or polyunsaturated fatty acids or protenoic acid may exhibit anti-inflammatory activity; possible anti-inflammatory activity of polyunsaturated fatty acids is neither described nor suggested.
La demande Internationale WO 03/045168 décrit des formulations à base d'acides gras poly-insaturés en Cl 8. Ces formulations permettent en particulier l'utilisation de ces acides gras poly-insaturés en Cl 8 trans/cis conjugués, avec leurs propriétés connues : action sur les triglycérides ou le cholestérol ou la prise de poids, maladies cardiovasculaires, prévention des cancers, propriétés anti-artérioscléroses, prévention ou traitement des allergies.International Application WO 03/045168 describes formulations based on polyunsaturated fatty acids at Cl 8. These formulations allow in particular the use of these conjugated trans-cis-C 18 polyunsaturated fatty acids, with their known properties. : action on triglycerides or cholesterol or weight gain, cardiovascular diseases, cancer prevention, anti-arteriosclerotic properties, prevention or treatment of allergies.
Il est connu que certains acides gras conjugués octadécatriénoïques sont des inhibiteurs de la biosynthèse des prostaglandines (Naturally occuring conjugated octadecatrienoic acids are strong inhibitors of prostaglandin biosynthesis ; de NugterenIt is known that certain octadecatrienoic conjugated fatty acids are inhibitors of prostaglandin biosynthesis (Naturally occuring conjugated octadecatrienoic acids are strong inhibitors of prostaglandin biosynthesis of Nugteren
D.H. et al.). Toutefois, cet article ne fait référence qu'à des résultats obtenus in vitro, sur des microsomes de mouton. Ces résultats ne peuvent préjuger de l'activité in vivo des produits testés. De plus, la tolérance de ces produits in vivo n'a pas été testée.DH et al.). However, this article only refers to results obtained in vitro, on sheep microsomes. These results can not prejudge the in vivo activity of the products tested. In addition, the tolerance of these products in vivo has not been tested.
L'étude menée par Nugteren et al. a été réalisée dans des conditions basai es, c'est-à-dire sans inflammation. Cette étude ne permet pas de préjuger de l'activité des produits testés dans une situation inflammatoire, notamment lors de l'application de ces produits sur une peau ou des muqueuses inflammée(s).The study conducted by Nugteren et al. was carried out under basic conditions, that is to say without inflammation. This study does not make it possible to prejudge the activity of the products tested in an inflammatory situation, in particular when the application of these products on an inflamed skin or mucous membranes.
D'une manière surprenante, les inventeurs ont découvert que les triènes d'acide gras conjugués et éventuellement oxygénés d'origine synthétique et/ou naturelle peuvent être utilisés dans le traitement de l'inflammation et/ou pour favoriser la cicatrisation.Surprisingly, the inventors have discovered that conjugated and optionally oxygenated fatty acid trienes of synthetic and / or natural origin can be used in the treatment of inflammation and / or to promote healing.
La présente invention a donc pour objet l'utilisation d'une composition comprenant au moins un acide gras choisi dans le groupe constitué par l'acide alpha- éléostéarique, l'acide catalpique, l'acide calendique, l'acide jacarique, l'acide licanique et l'acide béta-éléostéarique, pour la fabrication d'un médicament destiné à la prévention et/ou au traitement des maladies inflammatoires et/ou des désordres métaboliques consécutifs à une inflammation de la peau, des muqueuses et/ou des cartilages. En alternative, la composition peut comprendre l'acide alpha linolénique, seul ou en mélange avec au moins un acide gras conjugué précité.The subject of the present invention is therefore the use of a composition comprising at least one fatty acid chosen from the group consisting of alpha-eleostearic acid, catalpic acid, calendrical acid, jacaric acid, licanic acid and beta-eleostearic acid, for the manufacture of a medicament for the prevention and / or treatment of inflammatory diseases and / or metabolic disorders resulting from inflammation of the skin, mucous membranes and / or cartilage . Alternatively, the composition may comprise alpha-linolenic acid, alone or in admixture with at least one conjugated fatty acid.
Dans le cadre de la présente invention, on entend par l'expression « désordres métaboliques consécutifs à une inflammation de la peau, des muqueuses et/ou des cartilages » toutes les maladies en rapport avec une perturbation du métabolisme, ladite perturbation du métabolisme étant induite ou consécutive à une inflammation. Ces désordres métaboliques ont donc pour point commun une inflammation de la peau, des muqueuses et/ou des cartilages et ils correspondent aux effets principaux ou secondaires de ladite inflammation.In the context of the present invention, the expression "metabolic disorders consecutive to an inflammation of the skin, mucous membranes and / or cartilage" is understood to mean all diseases related to a disturbance of the metabolism, said disturbance of the metabolism being induced. or following inflammation. These metabolic disorders therefore have in common inflammation of the skin, mucous membranes and / or cartilage and they correspond to the main or secondary effects of said inflammation.
Les muqueuses sont avantageusement choisies dans le groupe constitué par les muqueuses buccales, gingivales, broncho pulmonaires, auriculaires, nasales, intestinales rectales ou vaginales.The mucous membranes are advantageously chosen from the group consisting of oral, gingival, broncho-pulmonary, auricular, nasal, rectal or vaginal intestinal mucosa.
L'acide alpha-éléostéarique répond à la formule suivante :Alpha-eleostearic acid has the following formula:
L'acide catalpique répond à la formule suivante : The catalpic acid has the following formula:
L'acide calendique répond à la formule suivante :The calendrical acid has the following formula:
L'acide jacarique répond à la formule suivante :The jacaric acid corresponds to the following formula:
L'acide punicique répond à la formule suivante :Punic acid has the following formula:
L'acide licanique répond à la formule générale suivante :The licanic acid has the following general formula:
L'acide béta-éléostéarique répond à la formule suivante :Beta-eleostearic acid has the following formula:
Selon une autre variante avantageuse de l'invention, la composition selon l'invention comprend au moins l'acide α-éléostéarique et/ou l'acide catalpique. Selon une variante avantageuse de l'invention, l'acide gras conjugué est choisi dans le groupe constitué par l'acide alpha-éléostéarique et l'acide catalpique, seuls ou en mélange.According to another advantageous variant of the invention, the composition according to the invention comprises at least α-eleostearic acid and / or catalpic acid. According to an advantageous variant of the invention, the conjugated fatty acid is chosen from the group consisting of alpha-eleostearic acid and catalpic acid, alone or as a mixture.
Dans le cadre de la présente invention, l'inflammation peut avoir une origine physique (chaleur, froid, radiations ionisantes, infra-rouges, rayonnement solaire), mécanique (frottement), chimique (contact avec des produits irritants ou allergisants tels qu'un parfum ou des produits chimiques) ou biologique (microbe, champignon).In the context of the present invention, the inflammation may have a physical origin (heat, cold, ionizing radiation, infra-red radiation, solar radiation), mechanical (friction), chemical (contact with irritants or allergens such as a perfume or chemicals) or biological (microbe, mushroom).
Selon une variante de l'invention, l'inflammation est due aux rayonnements solaires, à des radiations ionisantes, aux infra rouges, à la chaleur ou au froid. Le médicament est alors avantageusement destiné à la prévention et/ou au traitement des maladies choisies dans le groupe constitué par les cancers cutanés, l'érythème solaire et la lucite estivale bénigne. Les cancers cutanés peuvent faire suite à une inflammation de la peau due à l'exposition solaire, telle que par exemple un coup de soleil. Lesdits cancers cutanés pouvant être traités dans le cadre de la présente invention sont en particulier choisis dans le groupe constitué par le cancer basocellulaire, le cancer spinocellulaire ou le mélanôme malin.According to a variant of the invention, the inflammation is due to solar radiation, ionizing radiation, infrared, heat or cold. The drug is then advantageously intended for the prevention and / or treatment of diseases selected from the group consisting of cutaneous cancers, solar erythema and benign summer lucitis. Skin cancers can follow inflammation of the skin due to sun exposure, such as sunburn. Said skin cancers that can be treated in the context of the present invention are in particular chosen from the group consisting of basal cell cancer, squamous cell cancer or malignant melanoma.
Selon une autre variante de l'invention, le médicament est destiné à la prévention et/ou au traitement des réactions allergiques et/ou irritatives de la peau et/ou des muqueuses. Le médicament selon l'invention est également approprié pour favoriser la cicatrisation, dans les processus de cicatrisation normaux ou pathologiques, tels que les ulcères et les escarres.According to another variant of the invention, the medicament is intended for the prevention and / or treatment of allergic and / or irritative reactions of the skin and / or mucous membranes. The drug according to the invention is also suitable for promoting healing, in normal or pathological healing processes, such as ulcers and pressure ulcers.
Le médicament selon l'invention est avantageusement destiné à la prévention et/ou au traitement des maladies choisies dans le groupe constitué par l'eczéma atopique, les dermatoses inflammatoires telles que le psoriasis, les dermites irritatives, l'acné, la dermite séborrhéique, l'eczéma nummulaire, l'eczéma dyshidrosique, leThe drug according to the invention is advantageously intended for the prevention and / or treatment of diseases selected from the group consisting of atopic eczema, inflammatory dermatoses such as psoriasis, irritative dermatitis, acne, seborrheic dermatitis, nummular eczema, dyshidrotic eczema,
Pytiriasis alba, l'eczéma craquelé, les eczéma nutritionnels, l'urticaire, les dermatoses parasitaires, les dermatoses virales, les dermatoses fongiques ou bactériennes, l'intertrigo, les troubles de la vascularisation topique inflammatoires, l'ulcère du pied et/ou les piqûres d'insectes.Pytiriasis alba, cracked eczema, nutritional eczema, urticaria, parasitic dermatoses, viral dermatoses, fungal or bacterial dermatoses, intertrigo, inflammatory topical vascularization disorders, foot ulcer and / or insect bites.
Dans le cadre de la présente invention, le médicament est avantageusement destiné à la prévention et/ou au traitement des maladies choisies dans le groupe constitué par les gingivites et les parodontites.In the context of the present invention, the drug is advantageously intended for the prevention and / or treatment of diseases selected from the group consisting of gingivitis and periodontitis.
Le médicament est également avantageusement destiné à la prévention et/ou au traitement des maladies choisies dans le groupe constitué par les vulvites et les vaginites.The medicament is also advantageously intended for the prevention and / or treatment of diseases selected from the group consisting of vulvitis and vaginitis.
Enfin, le médicament est aussi avantageusement destiné à la prévention et/ou au traitement des maladies choisies dans le groupe constitué par l'arthrite et l'arthrose.Finally, the drug is also advantageously intended for the prevention and / or treatment of diseases selected from the group consisting of arthritis and osteoarthritis.
L'acide alpha linolénique a déjà été décrit comme agent anti-inflammatoire (EP 0 226 468). Les inventeurs ont découvert qu'il pouvait également être utilisé pour la fabrication d'un médicament destiné à la prévention et/ou au traitement des maladies inflammatoires et/ou des désordres métaboliques consécutifs à une inflammation de la peau, des muqueuses et/ou des cartilages. En particulier, l'acide alpha linolénique peut être utilisé pour la fabrication d'un médicament destiné au traitement :Alpha linolenic acid has already been described as an anti-inflammatory agent (EP 0 226 468). The inventors have discovered that it can also be used for the manufacture of a medicament for the prevention and / or treatment of inflammatory diseases and / or metabolic disorders resulting from inflammation of the body. skin, mucous membranes and / or cartilage. In particular, alpha-linolenic acid can be used for the manufacture of a medicament for treatment:
- des cancers cutanés, de Pérythème solaire et de la lucite estivale bénigne, en particulier le cancer basocellulaire, le cancer spinocellulaire ou le mélanôme malin ; des réactions allergiques et/ou irritatives de la peau et/ou des muqueuses ; lors de la cicatrisation ; des maladies choisies dans le groupe constitué par l'eczéma atopique, les dermatoses inflammatoires telles que le psoriasis, les dermites irritatives, l'acné, la dermite séborrhéique, l'eczéma nummulaire, l'eczéma dyshidrosique, le Pytiriasis alba, l'eczéma craquelé, les eczéma nutritionnels, l'urticaire, les dermatoses parasitaires, les dermatoses virales, les dermatoses fongiques ou bactériennes, Pintertrigo, les troubles de la vascularisation topique inflammatoires, l'ulcère du pied et/ou les piqûres d'insectes ; - des gingivites et des parodontites ;skin cancers, solar erythema and benign summer lucitis, in particular basal cell cancer, squamous cell carcinoma or malignant melanoma; allergic and / or irritative reactions of the skin and / or mucous membranes; during healing; diseases selected from the group consisting of atopic eczema, inflammatory dermatoses such as psoriasis, irritative dermatitis, acne, seborrheic dermatitis, nummular eczema, dyshidrotic eczema, Pytiriasis alba, eczema crackling, nutritional eczema, urticaria, parasitic dermatoses, viral dermatoses, fungal or bacterial dermatoses, intertrigo, inflammatory topical vascularization disorders, foot ulcer and / or insect bites; - gingivitis and periodontitis;
- des vulvites et des vaginites ;vulvitis and vaginitis;
- de l'arthrite et de l'arthrose.- arthritis and osteoarthritis.
La présente invention a également pour objet l'utilisation d'une composition comprenant au moins un acide gras choisi dans le groupe constitué par l'acide alpha- éléostéarique, l'acide catalpique, l'acide calendique, l'acide jacarique, l'acide licanique et l'acide béta-éléostéarique, pour le traitement cosmétique des peaux et/ou des muqueuses sensibles, irritées, intolérantes, à tendance allergique, âgées, présentant un trouble de la barrière cutanée, présentant des rougeurs cutanées ou présentant un déséquilibre immunologique non pathologique lié au vieillissement intrinsèque, extrinsèque ou hormonal. L'acide alpha linolénique peut également être utilisé dans une composition cosmétique pour le traitement cosmétique des peaux et/ou des muqueuses sensibles, irritées, intolérantes, à tendance allergique, âgées, présentant un trouble de la barrière cutanée, présentant des rougeurs cutanées ou présentant un déséquilibre immunologique non pathologique lié au vieillissement intrinsèque, extrinsèque ou hormonal. Dans le cadre de la présente invention, le traitement cosmétique peut consister en l'application ou l'ingestion d'une composition cosmétique ou nutraceutique respectivement.The present invention also relates to the use of a composition comprising at least one fatty acid selected from the group consisting of alpha-eleostearic acid, catalpic acid, calendrical acid, jacaric acid, licanic acid and beta-eleostearic acid, for the cosmetic treatment of skins and / or mucous membranes that are sensitive, irritated, intolerant, have an allergic tendency, are aged, have a skin barrier disorder, have skin rashes or have an immunological imbalance non-pathological related to intrinsic aging, extrinsic or hormonal. Alpha-linolenic acid may also be used in a cosmetic composition for the cosmetic treatment of skins and / or mucous membranes that are sensitive, irritated, intolerant, have an allergic tendency, are elderly, have a cutaneous barrier disorder, have cutaneous redness or exhibit a non-pathological immunological imbalance related to intrinsic, extrinsic or hormonal aging. In the context of the present invention, the cosmetic treatment may consist of the application or the ingestion of a cosmetic or nutraceutical composition respectively.
La présente invention a aussi pour objet l'utilisation d'une composition comprenant au moins un acide gras conjugué choisi dans le groupe constitué par l'acide alpha-éléostéarique, l'acide catalpique, l'acide calendique, l'acide jacarique, l'acide licanique et l'acide béta-éléostéarique, pour le traitement cosmétique de la cellulite.The subject of the present invention is also the use of a composition comprising at least one conjugated fatty acid chosen from the group consisting of alpha-eleostearic acid, catalpic acid, calendrical acid, jacaric acid, licanic acid and beta-eleostearic acid, for the cosmetic treatment of cellulite.
L'acide alpha linolénique peut également être utilisé dans une composition cosmétique pour le traitement cosmétique de la cellulite. La cellulite est une inflammation du tissu cellulaire localisée essentiellement sous la peau dans des régions prédisposées (cuisses, hanches, fesses). La cellulite correspond à une inflammation du tissu cellulaire sous-cutané, et se manifeste par une induration de la région atteinte. Ce phénomène peut être dû à une insuffisance de débit de la microcirculation locale qui altère les échanges entre le sang et les tissus cellulaires, ce qui entraîne une fixation excessive d'eau, de graisse, et une accumulation de déchets au niveau des cellules. Cela se manifeste par des masses adipeuses dures, en "capitons", qui tendent douloureusement la peau, souvent aux mêmes endroits: à l'intérieur et/ou à l'extérieur des cuisses, sur les hanches, les fesses, le ventre et la poitrine, et parfois aux bras et à la nuque. La présence de cellulite peut ne pas être liée au poids de la personne. Dans le cadre de la présente invention, la composition comprenant au moins un acide gras conjugué choisi dans le groupe constitué par l'acide alpha-éléostéarique, l'acide catalpique, l'acide calendique, l'acide jacarique, l'acide licanique et l'acide béta- éléostéarique peut être formulée sous la forme de différentes préparations adaptées à une administration topique, orale, rectale, vaginale, nasale, auriculaire, bronchique, ou parentérale. La composition selon l'invention est avantageusement formulée pour une administration par voie topique ou orale. En alternative, la composition peut comprendre l'acide alpha linolénique, seul ou en mélange avec au moins un acide gras conjugué précité.Alpha linolenic acid can also be used in a cosmetic composition for the cosmetic treatment of cellulite. Cellulite is an inflammation of the cell tissue located mainly under the skin in predisposed areas (thighs, hips, buttocks). Cellulitis is an inflammation of the subcutaneous cell tissue, and is manifested by induration of the affected area. This phenomenon may be due to insufficient flow of the local microcirculation which alters the exchanges between the blood and the cellular tissues, which leads to an excessive fixation of water, fat, and an accumulation of waste at the level of the cells. This is manifested by hard adipose masses, "cellulite", which tend painfully the skin, often in the same places: inside and / or outside the thighs, on the hips, buttocks, belly and the chest, and sometimes on the arms and neck. The presence of cellulite may not be related to the weight of the person. In the context of the present invention, the composition comprising at least one conjugated fatty acid selected from the group consisting of alpha-eleostearic acid, catalpic acid, calendrical acid, jacaric acid, licanic acid and Beta-eleostearic acid can be formulated in the form of various preparations suitable for topical, oral, rectal, vaginal, nasal, atrial, bronchial, or parenteral administration. The composition according to the invention is advantageously formulated for topical or oral administration. Alternatively, the composition may comprise alpha-linolenic acid, alone or in admixture with at least one conjugated fatty acid.
Lorsque la composition est adaptée pour une administration par voie topique, les différentes formulation peuvent inclure les crèmes, les pommades, les lotions, les huiles, les patches, les sprays ou tout autres produits pour application externe. La composition destinée à être administrée par voie topique comprend avantageusement 0,001 à 50% en poids, encore plus avantageusement 0,5 à 20% en poids, d'au moins un acide gras conjugué choisi dans le groupe constitué par l'acide α- éléostéarique, l'acide catalpique, l'acide calendique, l'acide jacarique, l'acide licanique et l'acide β- éléostéarique, par rapport au poids total de ladite composition.When the composition is adapted for topical administration, the various formulations may include creams, ointments, lotions, oils, patches, sprays or any other products for external application. The composition to be administered topically advantageously comprises 0.001 to 50% by weight, still more preferably 0.5 to 20% by weight, of at least one conjugated fatty acid selected from the group consisting of α-eleostearic acid. , catalpic acid, calendrical acid, jacaric acid, licanic acid and β-eleostearic acid, relative to the total weight of said composition.
Selon une variante avantageuse de l'invention, la composition administrée par voie topique comprend 0,001 à 50% en poids, avantageusement 0,5 à 20% en poids, encore plus avantageusement 1 à 10% en poids, d'acide alpha-éléostéarique et 0,001 àAccording to an advantageous variant of the invention, the composition administered topically comprises 0.001 to 50% by weight, advantageously 0.5 to 20% by weight, still more advantageously 1 to 10% by weight, of alpha-eleostearic acid and 0.001 to
50% en poids, avantageusement 0,5 à 20% en poids, encore plus avantageusement 1 à 10% en poids, d'acide catalpique, par rapport au poids total de ladite composition.50% by weight, advantageously 0.5 to 20% by weight, still more advantageously 1 to 10% by weight, of catalpic acid, relative to the total weight of said composition.
Selon une autre variante de l'invention, la composition administrée par voie topique comprend avantageusement 0,001 à 50% en poids, avantageusement 0,5 à 20% en poids, encore plus avantageusement 1 à 10% en poids, d'acide alpha-éléostéarique, par rapport au poids total de ladite composition. Lorsque le médicament ou la composition cosmétique est administré per os, il peut être administré sous formes unitaires ou multidoses d'administration en mélange avec des supports pharmaceutiques ou cosmétiques adéquats connus de l'homme du métier. Les formes unitaires d'administration appropriées comprennent notamment les comprimés éventuellement sécables, les gélules, les poudres, les granulés et les solutions ou suspensions orales. Les formes multidoses d'administration appropriées comprennent notamment les gouttes buvables, les émulsions et les sirops. La composition peut être formulée sous la forme d'un complément alimentaire.According to another variant of the invention, the composition administered topically advantageously comprises 0.001 to 50% by weight, advantageously 0.5 to 20% by weight, still more advantageously 1 to 10% by weight, of alpha-eleostearic acid. , relative to the total weight of said composition. When the drug or the cosmetic composition is administered orally, it may be administered in unit or multidose administration forms in admixture with suitable pharmaceutical or cosmetic carriers known to those skilled in the art. Suitable unit dosage forms include, optionally, scored tablets, capsules, powders, granules and oral solutions or suspensions. Suitable multidose forms of administration include oral drops, emulsions and syrups. The composition may be formulated as a dietary supplement.
Lors de la préparation de comprimés, le ou les acides gras conjugués selon l'invention sont mélangés avec un véhicule pharmaceutiquement ou cosmétiquement acceptable tel que notamment la gélatine, le talc, l'amidon, le lactose, le stéarate de magnésium, la gomme arabique ou leurs analogues. Les comprimés peuvent éventuellement être enrobés, c'est-à-dire recouverts de plusieurs couches de substances diverses telles que du saccharose, afin de faciliter la prise ou la conservation. Les comprimés peuvent encore présenter une formulation plus ou moins complexe destinée à modifier la vitesse de libération du principe actif. La libération du principe actif dudit comprimé peut être accélérée, ralentie ou retardée en fonction de l'absorption désirée. On obtient une préparation en gélules en mélangeant le ou les acides gras conjugués selon l'invention avec un diluant. Le mélange ainsi obtenu est versé dans des gélules molles ou dures. Une préparation sous forme de sirop peut contenir le ou les acides gras conjugués selon l'invention conjointement avec un édulcorant, avantageusement acalorique, un agent donnant du goût et un colorant approprié. Les poudres ou les granulés dispersibles dans l'eau peuvent comprendre le ou les acides gras conjugués selon l'invention en mélange avec des agents de dispersion ou des agents mouillants, des agents de mise en suspension, comme la polyvinypyrrolidone, ou des édulcorants ou des correcteurs de goût. La composition administrée par voie orale comprend avantageusement 0,001% àDuring the preparation of tablets, the conjugated fatty acid (s) according to the invention are mixed with a pharmaceutically or cosmetically acceptable vehicle such as, in particular, gelatin, talc, starch, lactose, magnesium stearate, gum arabic or their analogues. The tablets may optionally be coated, that is to say covered with several layers of various substances such as sucrose, to facilitate the setting or storage. The tablets may still have a more or less complex formulation intended to modify the rate of release of the active ingredient. The release of the active ingredient of said tablet can be accelerated, slowed down or delayed depending on the desired absorption. A preparation in capsules is obtained by mixing the conjugated fatty acid (s) according to the invention with a diluent. The mixture thus obtained is poured into soft or hard gelatin capsules. A syrup preparation may contain the conjugated fatty acid (s) according to the invention together with a sweetener, preferably a sweetener, a flavoring agent and a suitable dye. The water-dispersible powders or granules may comprise the conjugated fatty acid (s) according to the invention in admixture with dispersants or wetting agents, suspending agents, such as polyvinypyrrolidone, or sweeteners or preservatives. taste correctors. The composition administered orally advantageously comprises 0.001% to
100% en poids, encore plus avantageusement 1 à 50% en poids, d'au moins un acide gras conjugué choisi dans le groupe constitué par l'acide α-éléostéarique, l'acide catalpique, l'acide calendique, l'acide jacarique, l'acide licanique et l'acide β- éléostéarique, par rapport au poids total de ladite composition Selon une variante avantageuse de l'invention, la composition administrée par voie orale comprend 0,001 à 100% en poids, avantageusement 1 à 50% en poids, d'acide alpha-éléostéarique, et 0,001 à 100% en poids, avantageusement 1 à 50% en poids, d'acide catalpique, par rapport au poids total de ladite composition.100% by weight, more preferably 1 to 50% by weight, of at least one conjugated fatty acid selected from the group consisting of α-eleostearic acid, catalpic acid, calendrical acid, jacaric acid , licanic acid and β-eleostearic acid, relative to the total weight of said composition According to an advantageous variant of the invention, the composition administered orally comprises 0.001 to 100% by weight, advantageously 1 to 50% by weight. weight, alpha-eleostearic acid, and 0.001 to 100% by weight, preferably 1 to 50% by weight, of catalpic acid, relative to the total weight of said composition.
Selon une autre variante de l'invention, la composition administrée par voie orale comprend 0,001 à 100% en poids, avantageusement 1 à 50% en poids, d'acide alpha-éléostéarique, par rapport au poids total de ladite composition.According to another variant of the invention, the composition administered orally comprises 0.001 to 100% by weight, advantageously 1 to 50% by weight, of alpha-eleostearic acid, relative to the total weight of said composition.
Lorsque la composition selon l'invention est formulée sous la forme d'un complément alimentaire, ledit complément alimentaire peut comprendre jusqu'à 100% en poids de principes actifs selon l'invention c'est à dire des acides gras particuliers définis dans la présente invention.When the composition according to the invention is formulated in the form of a dietary supplement, said dietary supplement may comprise up to 100% by weight of active ingredients according to the invention, ie particular fatty acids defined in the present invention. invention.
La quantité de principes actifs que comprendra la composition selon l'invention dépend principalement du mode d'administration et de la forme galénique choisie.The amount of active ingredients that will comprise the composition according to the invention depends primarily on the mode of administration and the chosen dosage form.
Les modes d'administration, les posologies et les formes galéniques optimales des compositions selon l'invention peuvent être déterminés selon les critères généralement pris en compte dans l'établissement d'un traitement pharmaceutique, en particulier dermatologique, ou cosmétique adapté à un patient comme par exemple l'âge ou le poids corporel du patient, la gravité de son état général, la tolérance au traitement, les effets secondaires constatés, le type de peau. En fonction du type d'administration souhaitée, le médicament et/ou les composés actifs selon l'invention peuvent en outre comprendre au moins un excipient pharmaceutiquement acceptable, notamment dermatologiquement acceptable, ou cosmétiquement acceptable. De préférence, on utilise un excipient adapté pour une administration par voie topique externe ou orale. Le médicament ou la composition cosmétique selon la présente invention peut en outre comprendre au moins un adjuvant pharmaceutiquement ou cosmétiquement connu de l'homme du métier, choisi parmi les épaississants, les conservateurs, les parfums, les colorants, des filtres chimiques ou minéraux, les agents hydratants, les eaux thermales, etc. Le médicament selon l'invention est destiné au traitement et/ou à la prévention de maladies pouvant affecter l'être humain et/ou les animaux, notamment les mammifères.The modes of administration, the dosages and the optimum dosage forms of the compositions according to the invention can be determined according to the criteria generally taken into account in the establishment of a pharmaceutical treatment, in particular a dermatological treatment, or a cosmetic treatment adapted to a patient such as eg age or body weight of patient, severity of general condition, tolerance to treatment, the side effects noted, the type of skin. Depending on the type of administration desired, the drug and / or the active compounds according to the invention may further comprise at least one pharmaceutically acceptable excipient, in particular dermatologically acceptable, or cosmetically acceptable. Preferably, an excipient suitable for topical external or oral administration is used. The medicament or the cosmetic composition according to the present invention may further comprise at least one adjuvant which is pharmaceutically or cosmetically known to those skilled in the art, chosen from thickeners, preservatives, perfumes, dyes, chemical or mineral filters, moisturizers, thermal waters, etc. The medicament according to the invention is intended for the treatment and / or prevention of diseases that may affect humans and / or animals, especially mammals.
Le médicament ou la composition cosmétique selon l'invention peut en outre comprendre, en association, avantageusement avec un effet de synergie, au moins un composé choisi dans le groupe constitué par les émollients, les actifs hydratants, les activateurs de la synthèse de kératine, les kératorégulateurs, les kératolytiques, les agents restructurant de la barrière cutanée (activateurs de la synthèse des lipides cutanés), les activateurs de la différenciation des kératinocytes (rétinoïdes ou des rétinoïdes like, calcidone®, le calcium), des modulateurs de la différenciation de l'épidémie, des agents consolidant la jonction dermo épidermique, les antibiotiques, les agents anti-bactériens, les composés antifongiques, les agents anti-viraux, des stimulants de l'immunité innée (peptides antibiotiques naturels ) ou acquise, les sébo- régulateurs, tels que les inhibiteurs de 5-alpha réductase, notamment l'actif 5-alpha Avocuta® commercialisé par les Laboratoires Expanscience ou les sels de zinc et le sabal (Sabalinae de la sous-famille Coryphoideaé), les immunomodulateurs, tels que le tacrolimus, le pimécrolimus, les oxazolines, les conservateurs, les agents anti-irritants, les agents apaisants, des filtres et écrans solaires, les agents anti-oxydants, les facteurs de croissance, les agents cicatrisants ou les molécules eutrophiques, les médicaments et les agents anti-inflammatoires, et les composés contenant des insaponifiables d'huiles végétales. Selon une variante avantageuse de l'invention, la composition comprend en association, avantageusement avec un effet de synergie, des principes actifs choisis dans le groupe constitué par les agents anti-inflammatoires. Les activateurs de la synthèse de kératine pouvant être utilisés en association, avantageusement avec un effet de synergie, avec les acides gras conjugués sont avantageusement les rétinoïdes ou des rétinoïdes like , les peptides de lupin commercialisés par la société Silab, des protéines clés du stratum corneum ou granulosum (kératines).The medicament or the cosmetic composition according to the invention may further comprise, in combination, advantageously with a synergistic effect, at least one compound chosen from the group consisting of emollients, moisturizing active agents, activators of keratin synthesis, keratoregulators, keratolytics, skin barrier restructuring agents (activators of cutaneous lipid synthesis), activators of differentiation of keratinocytes (retinoids or retinoids like, calcidone®, calcium), modulators of the differentiation of the epidermis, agents strengthening the epidermal dermal junction, antibiotics, anti-bacterial agents, antifungal compounds, anti-viral agents, stimulants of innate immunity (natural antibiotic peptides) or acquired, the sebo-regulators , such as the 5-alpha reductase inhibitors, in particular the 5-alpha Avocuta® active agent marketed by Laborato Expanscience or the salts of zinc and sabal (Sabalinae of the subfamily Coryphoideae), immunomodulators, such as tacrolimus, pimecrolimus, oxazolines, preservatives, anti-irritants, soothing agents, filters and sunscreens, anti-oxidants, growth factors, healing agents or eutrophic molecules, drugs and anti-inflammatory agents, and compounds containing vegetable oil unsaponifiables. According to an advantageous variant of the invention, the composition comprises, in combination, advantageously with a synergistic effect, active principles chosen from the group consisting of anti-inflammatory agents. The activators of keratin synthesis that can be used in combination, advantageously with a synergistic effect, with the conjugated fatty acids are advantageously retinoids or retinoids like, the lupine peptides marketed by Silab, key proteins of the stratum corneum. or granulosum (keratins).
Les antibiotiques pouvant être utilisés en association, avantageusement avec un effet de synergie, avec les acides gras conjugués sont avantageusement l'acide fucidique, la pénicilline, les tétracyclines, la pristinamycine, l'érythromycine, la clindamycine, la mupirocine, la minocycline, la doxycycline. Les agents anti-viraux pouvant être utilisés en association avec les acides gras conjugués sont avantageusement l'acyclovir et le valacyclovir.The antibiotics that can be used in combination, advantageously with a synergistic effect, with the conjugated fatty acids are advantageously fucidic acid, penicillin, tetracyclines, pristinamycin, erythromycin, clindamycin, mupirocine, minocycline, doxycycline. The anti-viral agents that can be used in combination with the conjugated fatty acids are advantageously acyclovir and valacyclovir.
Les agents anti-irritants pouvant être utilisés dans le cadre de la présente invention en association, avantageusement avec un effet de synergie, avec les acides gras conjugués sont avantageusement la glycine, les sucres et/ou peptides de lupin, les sucres et/ou peptides d'avocat décrits dans les demandes de brevet FR0404635 etThe anti-irritant agents that can be used in the context of the present invention in combination, advantageously with a synergistic effect, with the conjugated fatty acids are advantageously glycine, sugars and / or peptides of lupine, sugars and / or peptides described in patent applications FR0404635 and
FR0404640, le Cyclocéramide®.FR0404640, Cycloceramide®.
Les agents apaisants pouvant être utilisés en association, avantageusement avec un effet de synergie, avec les acides gras conjugués sont avantageusement l'alpha bisabolol, les dérivés de réglisse, l'enoxolone (acide 3 bêta-hydroxy-l l-oxo-olean-12- en-30-oïque, numéro CAS 471-53-4). Les kératorégulateurs pouvant être utilisés en association avec les acides gras conjugués sont avantageusement les alpha hydroxy acides et leurs dérivés. Les kératolytiques pouvant notamment être utilisés en association avec les acides gras conjugués sont l'acide salicylique et ses dérivés : lipohydroxyacides. Les agents anti-oxydants pouvant être utilisés invention en association les acides gras conjugués sont avantageusement les vitamines (C, E), les oligo-éléments (cuivre, zinc, sélénium), les enzymes anti oxydants. Les facteurs de croissance pouvant être utilisés en association avantageusement avec un effet de synergie avec les acides gras conjugués sont avantageusement la becaplermine et le TGF-beta (Transforming Growth Factor beta). Les agents cicatrisants pouvant être utilisés en association avantageusement avec un effet de synergie, avec les acides gras conjugués sont avantageusement la vitamine A, le panthénol, l'Avocadofurane®, l'oxyde zinc, le magnésium, le silicium, l'acide madécassique ou asiatique, les polysaccharides de toutes origines et en particulier d'origine thermale marine ou les dérivés de d'huitre perlière.The soothing agents that can be used in combination, advantageously with a synergistic effect, with the conjugated fatty acids are advantageously alpha bisabolol, licorice derivatives, enoxolone (3-beta-hydroxy-1-oxo-olean acid). 12-en-30-oic, CAS No. 471-53-4). The kératorégulateurs that can be used in combination with the conjugated fatty acids are advantageously alpha hydroxy acids and their derivatives. The keratolytics that may especially be used in combination with the conjugated fatty acids are salicylic acid and its derivatives: lipohydroxyacids. The antioxidant agents that may be used in combination with the conjugated fatty acids are advantageously vitamins (C, E), trace elements (copper, zinc, selenium) and anti-oxidant enzymes. The growth factors that can advantageously be used in combination with a synergistic effect with the conjugated fatty acids are advantageously becaplermine and TGF-beta (Transforming Growth Factor beta). The healing agents which can advantageously be used in combination with a synergistic effect, with the conjugated fatty acids are advantageously vitamin A, panthenol, Avocadofurane®, zinc oxide, magnesium, silicon, acid madécassique or Asian, the polysaccharides of all origins and in particular of marine thermal origin or the derivatives of pearl oyster.
Les médicaments pouvant être utilisés dans le cadre de la présente invention, en association, avantageusement avec un effet de synergie, avec les acides gras conjugués, sont avantageusement les médicaments, appropriés pour une administration pour voie topique ou orale, pour la prévention et/ou le traitement de l'atopie (corticoïdes, émollients, immunomodulateurs), de l'acné (antibiotiques, peroxyde de benzoyle, rétinoïdes topiques et oraux, acide azélaïque, vitamine PP, zinc, cyclines), de l'eczéma (immunomodulateurs, émollients, huile de poisson, de bourrache, les pré et pro - biotiques) ou du psoriasis (corticoïdes, calcipotriol, calcitriol, tazarotène, huile de cade, acitrétine, PUVA thérapie, les dérivés de vitamine D). Le médicament peut également comprendre en association des stimulants de peptides antibiotiques tels que les sucres d'avocat et les peptides d'avocat.The medicaments that can be used in the context of the present invention, in combination, advantageously with a synergistic effect, with the conjugated fatty acids, are advantageously the drugs, suitable for administration for the topical or oral route, for the prevention and / or the treatment of atopy (corticosteroids, emollients, immunomodulators), acne (antibiotics, benzoyl peroxide, topical and oral retinoids, azelaic acid, vitamin PP, zinc, cyclins), eczema (immunomodulators, emollients, fish oil, borage, meadow and pro - biotic) or psoriasis (corticosteroids, calcipotriol, calcitriol, tazarotene, cade oil, acitretin, PUVA therapy, vitamin D derivatives). The drug may also include antibiotic peptide stimulants such as avocado sugars and avocado peptides.
Les agents anti-inflammatoires pouvant être utilisés en association, avantageusement avec un effet de synergie, avec les acides gras conjugués sont avantageusement des agents anti-inflammatoires stéroïdiens (AIS), tels que les corticoïdes, ou non-stéroïdiens (AINS) et les anti Cox 2 (celecoxib).The anti-inflammatory agents that can be used in combination, advantageously with a synergistic effect, with the conjugated fatty acids are advantageously steroidal anti-inflammatory agents (AIS), such as steroids, or non-steroids (NSAIDs) and anti-inflammatory agents. Cox 2 (celecoxib).
Les agents restructurant de la barrière cutanée, permettant de stimuler la synthèse des lipides clés de Pépiderme, et pouvant être utilisés en association, avantageusement avec un effet de synergie, avec les acides gras conjugués sont avantageusement des concentrats de tournesol, encore plus avantageusement des concentrats de tournesol linoléiques, tels que l'actif commercialisé par les Laboratoires Expanscience, Soline® (cf. la demande internationale WO 01/21150), des insaponifiables d'huile végétale, tel que l'Avocadofurane® (cf. la demande internationale WO 01/21150), des agonistes PPARs alpha, béta, gamma et delta (rosiglitazone, pioglitazone).Les agonistes RXR et RAR, des récepteurs à la vitamine D. Les composés antifongiques pouvant être utilisés en association avec les acides gras conjugués sont avantageusement Peconazole, le ketoconazole et le climbazole. On peut également utiliser en association des réducteurs tels que l'ichtyol. Les conservateurs antiseptiques pouvant être utilisés en association, avantageusement avec un effet de synergie, avec les acides gras conjugués peuvent être le triclosan, la chlorhéxidine, les ammoniums quaternaires. Les immunomodulateurs pouvant être utilisés en association, avantageusement avec un effet de synergie, avec les acides gras conjugués sont avantageusement le tacrolimus, le pimécrolimus et les oxazolines.The restructuring agents of the cutaneous barrier, which make it possible to stimulate the synthesis of the key lipids of the epidermis, and which can be used in combination, advantageously with a synergistic effect, with the conjugated fatty acids are advantageously concentrates of sunflower, even more advantageously concentrates. linoleic sunflower seeds, such as the active ingredient marketed by Laboratoires Expanscience, Soline® (see international application WO 01/21150), vegetable oil unsaponifiables, such as Avocadofurane® (see international application WO 01 / 21150), PPAR agonists alpha, beta, gamma and delta (rosiglitazone, pioglitazone). The RXR and RAR agonists, vitamin D receptors. The antifungal compounds that can be used in combination with the conjugated fatty acids are advantageously Peconazole, ketoconazole and climbazole. It is also possible to use reducing agents such as ichthyol in combination. The antiseptic preservatives that can be used in combination, advantageously with a synergistic effect, with the conjugated fatty acids may be triclosan, chlorhexidine or quaternary ammoniums. The immunomodulators which can be used in combination, advantageously with a synergistic effect, with the conjugated fatty acids are advantageously tacrolimus, pimecrolimus and oxazolines.
Les oxazolines pouvant être utilisées dans le cadre de la présente invention sont avantageusement des oxazolines choisies dans le groupe constitué par la 2-undécyl-4- hydroxyméthyl-4-méthyl-l,3-oxazoline, la 2-undécyl-4,4-dirnéthyl-l,3-oxazoline, laThe oxazolines which can be used in the context of the present invention are advantageously oxazolines chosen from the group consisting of 2-undecyl-4-hydroxymethyl-4-methyl-1,3-oxazoline and 2-undecyl-4,4-dimethylamine. dimethyl-1,3-oxazoline, the
(E)-4,4-diméthyl-2-heptadéc-8-ényl-l ,3-oxazoline, la 4-hydroxyméthyl-4-méthyl-2- heptadécyl- 1 ,3 -oxazoline, la (E)-4-hydroxyméthyl-4-méthyl-2-heptadéc-8-ényl- 1 ,3 - oxazoline, la 2-undécyl-4-éthyl-4-hydroxyméthyl- 1,3 -oxazoline. De manière encore plus avantageuse, ladite oxazoline est la 2-undécyl-4,4-diméthyl- 1,3 -oxazoline, appelée(E) -4,4-dimethyl-2-heptadec-8-enyl-1,3-oxazoline, 4-hydroxymethyl-4-methyl-2-heptadecyl-1,3-oxazoline, (E) -4- hydroxymethyl-4-methyl-2-heptadec-8-enyl-1,3-oxazoline, 2-undecyl-4-ethyl-4-hydroxymethyl-1,3-oxazoline. Even more advantageously, said oxazoline is 2-undecyl-4,4-dimethyl-1,3-oxazoline, called
OX-100 ou Cyclocéramide®.OX-100 or Cycloceramide®.
Les composés contenant des insaponifïables d'huiles végétales pouvant être utilisés en association, avantageusement avec un effet de synergie, avec les acides gras conjugués sont avantageusement choisis dans le groupe constitué par les lipides furaniques d'avocat, les insaponifïables d'avocat et de soja, les concentrats d'huile de lupin, les concentrats d'huile de tournesol et leurs mélanges. Les lipides furaniques d'avocat pouvant être utilisés dans le cadre de la présente invention sont avantageusement des 2-alkyl furanes naturels, notamment l'actif Avocadofurane® commercialisé par les Laboratoires Expanscience, pouvant être obtenus par le procédé décrit dans la demande internationale WO 01/21605. Les insaponifïables d'avocat et de soja pouvant être utilisés en association avec les acides gras conjugués sont avantageusement un mélange d'insaponifiables d'avocat furanique et d'insaponifïables de soja, dans un rapport respectif d'environ 1/3-2/3. Les insaponifïables d'avocat et de soja sont encore plus avantageusement le produit Piasclédine®, commercialisé par les Laboratoires Expanscience. Les concentrats d'huile de lupin pouvant être utilisés sont avantageusement des concentrats obtenus par distillation moléculaire d'huile de lupin, avantageusement d'huile de lupin blanc doux , tels que ceux décrits dans la demande internationale WO 98/47479. Ils contiennent avantageusement environ 60% en poids d'insaponifiables. Les concentrats d'huile de tournesol pouvant être utilisés sont avantageusement des concentrats de tournesol linoléiques, tels que l'actif commercialisé par les Laboratoires Expanscience, Soline® (cf. la demande internationale WOThe compounds containing vegetable oil unsaponifiables that can be used in combination, advantageously with a synergistic effect, with the conjugated fatty acids are advantageously chosen from the group consisting of avocado furan lipids, avocado and soya unsaponifiables. , lupine oil concentrates, sunflower oil concentrates and mixtures thereof. The furanic lipids of avocado that can be used in the context of the present invention are advantageously natural 2-alkyl furans, in particular the active Avocadofurane® sold by Laboratoires Expanscience, obtainable by the process described in international application WO 01 / 21605. The avocado and soya unsaponifiables which can be used in combination with the conjugated fatty acids are advantageously a mixture of unsaponifiables of furanic avocado and unsaponifiable soya, in a respective ratio of approximately 1 / 3-2 / 3 . The unsaponifiable avocado and soya are even more advantageously the product Piasclédine®, marketed by Laboratoires Expanscience. The lupine oil concentrates that may be used are advantageously concentrates obtained by molecular distillation of lupine oil, advantageously sweet white lupine oil, such as those described in the international application WO 98/47479. They advantageously contain about 60% by weight of unsaponifiables. The sunflower oil concentrates that can be used are advantageously linoleic sunflower concentrates, such as the active ingredient marketed by Laboratoires Expanscience, Soline® (see the international application WO
01/21150). Selon une variante avantageuse de l'invention, la source d'acide gras conjugué est un extrait lipidique d'au moins un végétal choisi dans le groupe constitué par les végétaux de la famille des Cucurbitaceés, des Punicacées, des Bignoniacées, des Euphorbiacées, des Compositées (Asteracées), des Balsaminacées, des Rosacées, des Chrysobalanacées, des Ricinocarpus et des Chilopsis. Plus particulièrement, la source acide gras conjugué est un extrait lipidique d'au moins un végétal choisi dans le groupe constitué par les Mormordica verts, blancs, perlés et sauvage, le Catalpa, PAleurites, l'Euphorbe, le Parinarium, le Licania, le Parinarium, le Calendula, le Punica, le grenadier, le bois de chine, le balsam, le Trichosanthès et le Centrarus, le Jacaranda . La source d'acide alpha-éléostéarique est avantageusement des huiles vierges et/ou raffinées d'au moins un végétal choisi dans le groupe constitué par le Momordica charantia, l'Aleuritès montana et l'Aleuritès fordii, le Parinarium montanum, le Parinarium excelsum, le Parinarium macrophyîlum, le Parinarium holstii, le Licania rigida et le Ricinocarpus bowmanii. La source d'acide catalpique est avantageusement des huiles vierges et/ou raffinées d'au moins un végétal choisi dans le groupe constitué par le Catalpa ovata, le Catalpa hignoniodes et le Chilopsis linearis. La source d'acide calandique est avantageusement une huile vierge et purifiée de Calendula officinalis. La source d'acide punicique est avantageusement des huiles vierges et/ou raffinées d'au moins un végétal choisi dans le groupe constitué par le Punica granatum, le Trichosanthès nervifolia et le Momordica balsamina. La source d'acide béta- éléostéarique est avantageusement une huile vierge et purifiée de Centratus ruber. La source d'acide licanique est avantageusement l'huile d'Oïticica, de Licania ou de Parinarium. Selon une variante avantageuse de l'invention, les huiles vierges et/ou raffinées précitées ne contiennent aucune trace de protéine détectable. La source d'acide alpha-éléostéarique et d'acide catalpique est plus particulièrement un extrait lipidique de graines de Mormordica, avantageusement de graines de Momordica charantia.01/21150). According to an advantageous variant of the invention, the source of conjugated fatty acid is a lipid extract of at least one plant selected from the group consisting of plants of the family Cucurbitaceae, Punicaceae, Bignoniaceae, Euphorbiaceae, Composites (Asteraceae), Balsaminaceae, Rosaceae, Chrysobalanaceae, Ricinocarpus and Chilopsis. More particularly, the conjugated fatty acid source is a lipid extract of at least one plant selected from the group consisting of green, white, pearly and wild Mormordica, Catalpa, Peerites, Euphorbia, Parinarium, Licania, Parinarium, Calendula, Punica, Pomegranate, Chinese Wood, Balsam, Trichosanthes and Centrarus, Jacaranda. The source of alpha-eleostearic acid is advantageously virgin and / or refined oils of at least one plant selected from the group consisting of Momordica charantia, Aleuritès montana and Aleuritès fordii, Parinarium montanum, Parinarium excelsum , Parinarium macrophyllum, Parinarium holstii, Licania rigida and Ricinocarpus bowmanii. The source of catalpic acid is advantageously virgin and / or refined oils of at least one plant selected from the group consisting of Catalpa ovata, Catalpa hignoniodes and Chilopsis linearis. The source of calandic acid is advantageously a virgin and purified oil of Calendula officinalis. The source of punicic acid is advantageously virgin and / or refined oils of at least one plant selected from the group consisting of Punica granatum, Trichosanthes nervifolia and Momordica balsamina. The source of beta-eleostearic acid is advantageously a virgin and purified oil of Centratus ruber. The source of licanic acid is advantageously Oitica, Licania or Parinarium oil. According to an advantageous variant of the invention, the virgin and / or refined oils mentioned above do not contain any trace of detectable protein. The source of alpha-eleostearic acid and catalpic acid is more particularly a lipid extract of Mormordica seeds, advantageously seeds of Momordica charantia.
Selon une variante avantageuse de l'invention, la composition selon l'invention administrée par voie topique comprend 0,001% à 50% en poids d'un extrait lipidique de graines de momordique, avantageusement 0,001% à 50% en poids, encore plus avantageusement 2 à 20% en poids, d'un extrait lipidique de graines de Momordica charantia, par rapport au poids total de la composition. Selon une autre variante avantageuse de l'invention, la composition selon l'invention administrée par voie orale comprend 0,001% à 100% en poids d'un extrait lipidique de graines de momordique, avantageusement 0,001% à 100% en poids d'extrait lipidique de graine de Momordica charantia, encore plus avantageusement 1 à 50% en poids d'un extrait lipidique de graines de Momordica charantia, par rapport au poids total de la composition.According to an advantageous variant of the invention, the composition according to the invention administered topically comprises 0.001% to 50% by weight of a lipid extract of momordic seeds, advantageously 0.001% to 50% by weight, even more advantageously 2 at 20% by weight, of a lipid extract of Momordica charantia seeds, relative to the total weight of the composition. According to another advantageous variant of the invention, the composition according to the invention administered orally comprises 0.001% to 100% by weight of a lipid extract of momordic seeds, advantageously 0.001% to 100% by weight of lipid extract seed of Momordica charantia, more advantageously 1 to 50% by weight of a lipid extract of Momordica charantia seeds, relative to the total weight of the composition.
L'extrait lipidique de graines de Momordica charantia comprend avantageusement au moins 20% en poids d'acide alpha-éléostéarique et d'acide catalpique, avantageusement au moins 40% en poids d'acide alpha-éléostéarique et d'acide catalpique, encore plus avantageusement environ 45% en poids d'acide alpha- éléostéarique et d'acide catalpique. Le mélange d'acide alpha-éléostéarique et d'acide catalpique comprend avantageusement au moins 50% en poids d'acide alpha- éléostéarique, avantageusement au moins 90% en poids d'acide alpha-éléostéarique, encore plus avantageusement au moins 98% en poids d'acide alpha-éléostéarique. Le margoze du genre Momordica charantia est une cucurbitacée tropicale qui provient de l'Inde mais qui est également cultivée sur l'île de la Réunion. C'est une herbacée annuelle, qui peut donner des lianes de 2 mètres de long, et dont les fruits oblongs de couleur verte contiennent des graines plates. La teneur en lipides de ces graines est de 30% environ en poids. L'extrait lipidique de Momordica charantia est susceptible d'être obtenu par un procédé consistant à extraire les lipides totaux des graines de Momordica charantia préalablement séchées et broyées, à l'aide d'un solvant des huiles, puis à évaporer ledit solvant ou selon le procédé consistant à extraire les lipides des graines de Momordica charantia par pression mécanique des graines à froid. Dans un mode de réalisation particulier selon la présente invention, l'huile des graines de Momordica charantia est susceptible d'être obtenue selon le procédé consistant à extraire les lipides totaux des graines de cucurbitacées préalablement séchées et broyées, à l'aide d'un solvant des huiles, puis à évaporer le solvant. Les graines de Momordica charantia selon la présente invention sont broyées par exemple à l'aide d'un broyeur à cylindre ou à marteaux. Le solvant des huiles, utilisé pour extraire les lipides totaux des graines formant l'huile, est un solvant organique classique d'extraction de lipides. Le solvant est avantageusement choisi dans le groupe constitué par les alcanes aliphatiques, les alcanes aromatiques, les alcools aliphatiques et leurs dérivés halogènes. De manière encore plus avantageuse selon la présente invention, le solvant organique est l'hexane. L'extraction des lipides totaux des graines de Momordica charantia est avantageusement réalisée par une extraction au soxhlet qui est une technologie bien connue de l'homme de métier. Après extraction des lipides contenus dans les graines de Momordica charantia selon la présente invention, le solvant organique est évaporé, de préférence par évaporation sous vide.The lipid extract of Momordica charantia seeds advantageously comprises at least 20% by weight of alpha-eleostearic acid and of catalpic acid, advantageously at least 40% by weight of alpha-eleostearic acid and of catalpic acid, and even more advantageously about 45% by weight of alpha-eleostearic acid and catalpic acid. The mixture of alpha-eleostearic acid and catalpic acid advantageously comprises at least 50% by weight of alpha-eleostearic acid, advantageously at least 90% by weight of alpha-eleostearic acid, still more advantageously at least 98% by weight. weight of alpha-eleostearic acid. The Margoze of the genus Momordica charantia is a tropical cucurbit that comes from India but is also grown on the island of Reunion. It is an annual herb, which can give lianas 2 meters long, and whose oblong fruits of green color contain flat seeds. The lipid content of these seeds is about 30% by weight. The lipid extract of Momordica charantia is obtainable by a process consisting in extracting the total lipids from the seeds of Momordica charantia previously dried and crushed, using a solvent of the oils, then evaporating said solvent or according to the process of extracting the lipids from the seeds of Momordica charantia by mechanical pressure of the seeds cold. In a particular embodiment according to the present invention, the oil of the seeds of Momordica charantia can be obtained according to the process of extracting the total lipids from the seeds of cucurbitaceae previously dried and crushed, with the aid of a solvent of the oils, then to evaporate the solvent. The seeds of Momordica charantia according to the present invention are milled for example using a roller mill or hammers. The oil solvent used to extract the total lipids from the oil-forming seeds is a conventional organic lipid extraction solvent. The solvent is advantageously chosen from the group consisting of aliphatic alkanes, aromatic alkanes, aliphatic alcohols and their halogenated derivatives. Even more advantageously according to the present invention, the organic solvent is hexane. The extraction of the total lipids from the seeds of Momordica charantia is advantageously carried out by a Soxhlet extraction which is a technology well known to those skilled in the art. After extraction of the lipids contained in the seeds of Momordica charantia according to the present invention, the organic solvent is evaporated, preferably by evaporation under vacuum.
Dans un autre mode de réalisation particulier selon la présente invention, l'huile des graines de Momordica charantia est susceptible d'être obtenue selon le procédé consistant à extraire les lipides des graines de cucurbitacées par pression mécanique des graines à froid, avantageusement à l'aide d'une presse à vis continue, pour conduire, après filtration, à des huiles vierges de première pression.In another particular embodiment according to the present invention, the seed oil of Momordica charantia can be obtained by the process of extracting the lipids from cucurbitaceae seeds by mechanical pressure of the cold seeds, advantageously with using a continuous screw press, to conduct, after filtration, virgin oils of first pressure.
Les extraits lipidiques des autres végétaux selon la présente invention sont susceptibles d'être obtenus par des procédés similaires aux procédés décrits ci- dessus.Les huiles du ou des végétaux selon la présente invention peuvent être utilisées brutes ou raffinées. Par raffinage, on entend au sens de la présente invention, les opérations unitaires de purification des lipides d'origine végétale bien connues de l'homme de métier, parmi lesquelles on peut citer notamment la neutralisation chimique, la démucilagination, la décoloration, la désodorisation et la frigélisation. Les huiles extraites des graines de Momordica charantia présentent l'avantage supplémentaire d'être des composés cosmétiquement acceptables, non agressifs pour la peau, non toxiques et hypoallergéniques.The lipid extracts of the other plants according to the present invention are capable of being obtained by methods similar to the processes described above. The oils of the plant (s) according to the present invention can be used raw or refined. For the purposes of the present invention, refining is understood to mean the unitary lipid purification operations of plant origin well known to those skilled in the art, among which may be mentioned in particular chemical neutralization, degumming, decolourisation, deodorization. and frigmentation. The oils extracted from Momordica charantia seeds have the additional advantage of being cosmetically acceptable, non-aggressive to the skin, non-toxic and hypoallergenic.
Les exemples suivants sont donnés à titre non limitatif et illustrent la présente invention. The following examples are given without limitation and illustrate the present invention.
Exemple 1 : formulations cosmétiques à base d'un extrait de Momordica charantiaExample 1 Cosmetic Formulations Based on a Momordica Charantia Extract
Crème anti acné n°lAnti-acne cream no.
Eau QSP 100%Water QSP 100%
Isononyl Isononanoate 7,000Isononyl Isononanoate 7,000
Di-C12-13 Alkyl Malate 7,000Di-C 12-13 Alkyl Malate 7,000
Stéarate isocétyle 5,000Isocetyl stearate 5,000
Butylène Glycol 3,000Butylene Glycol 3,000
Oriza Sativa 2,500Oriza Sativa 2,500
Extrait de Momordica charantia 2,000Momordica charantia extract
Dicaprylyl Ether 2,000Dicaprylyl Ether 2,000
Salicylate de silanediol 2,000Silanediol salicylate 2,000
Alcool arachique 1,650Arachic alcohol 1,650
Trométhamine 1,180Tromethamine 1,180
Alcool cétylique 1,000Cetyl alcohol 1,000
Acide salicylique 1,000Salicylic acid 1,000
Glucoside Ascorbyl 1,000Glucoside Ascorbyl 1,000
Glycine 1,000Glycine 1,000
Acétate de Tocopheryl 1,000Tocopheryl acetate 1,000
Alcool béhénylique 0,900Behenyl alcohol 0.900
Squalane 0,790Squalane 0.790
Citrate de sodium 0,660Sodium citrate 0.660
Copolymère PPG-12/SMDI 0,500PPG-12 / SMDI Copolymer 0.500
Glucoside Arachidyl 0,4500.450 Arachidyl Glucoside
Parfum 0,400Perfume 0.400
Gomme Sclerotium 0,160Gum Sclerotium 0.160
Alcool cétéarylique 0,130Cetearyl alcohol 0.130
Acide citrique 0,110Citric acid 0.110
Sepigel 305* 0,100Sepigel 305 * 0.100
Système conservateur QSConservative QS system
^produit commercialisé par la société Seppicproduct marketed by Seppic
QSP : Quantité Suffisante Pour ; QS : Quantité Suffisante ( Crème anti acné n°2QSP: Sufficient Quantity For; QS: Sufficient quantity (Anti-acne cream n ° 2
Eau QSP 100%Water QSP 100%
Isononyl Isononanoate 7,000Isononyl Isononanoate 7,000
Di-C12-I3 Alkyl Malate 7,000Di-C 12-I3 Alkyl Malate 7,000
Stéarate isocétyle 5,000Isocetyl stearate 5,000
Butylène Glycol 3,000Butylene Glycol 3,000
Oriza Sativa 2,500Oriza Sativa 2,500
Extrait de Momordica charantia L 2,000Momordica charantia extract L 2,000
5-alpha avocuta® 2,0005-alpha avocuta® 2,000
Dicaprylyl Ether 2,000Dicaprylyl Ether 2,000
Salicylate de silanediol 2,000Silanediol salicylate 2,000
Alcool arachique 1,650Arachic alcohol 1,650
Trométhamine 1,180Tromethamine 1,180
Alcool cétylique 1,000Cetyl alcohol 1,000
Acide salicylique 1,000Salicylic acid 1,000
Glucoside Ascorbyl 1,000Glucoside Ascorbyl 1,000
Glycine 1,000Glycine 1,000
Acétate de Tocopheryl 1,000Tocopheryl acetate 1,000
Alcool béhénylique 0,900Behenyl alcohol 0.900
Squalane 0,790Squalane 0.790
Citrate de sodium 0,660Sodium citrate 0.660
Copolymère PPG-12/SMDI 0,500PPG-12 / SMDI Copolymer 0.500
Glucoside Arachidyl 0,4500.450 Arachidyl Glucoside
Parfum 0,400Perfume 0.400
Gomme Sclerotium 0,160Gum Sclerotium 0.160
Alcool cétéarylique 0,130Cetearyl alcohol 0.130
Acide citrique 0,110Citric acid 0.110
Sepigel 305* 0,100Sepigel 305 * 0.100
Système conservateur QSConservative QS system
*produit commercialisé par la société Seppic Baindebouche* product marketed by the company Seppic Mouthwash
Extrait de Momordica charantia 0,1 à 10%Momordica charantia extract 0.1 to 10%
Alcool éthylique 10Ethyl alcohol 10
Glycérine 10Glycerin 10
Huile de ricin hydrogénée,Hydrogenated castor oil,
Ethoxylée à 40 moles EO 0,5Ethoxylated at 40 moles EO 0.5
(Crémophor co410)(Cremophor co410)
Poly(Methyl vinyl ether/ Acide Maléïque 0,2Poly (Methyl vinyl ether / Maleic Acid 0.2
(Gantrez S97BF)(Gantrez S97BF)
Soude 0,15Soda 0.15
Fluorure de sodium 0,050.05 sodium fluoride
Arôme Cannelle-Menthe 0,1Cinnamon-Mint aroma 0,1
Triclosan 0,03Triclosan 0.03
Chlorure de zinc 0,010.01 zinc chloride
Saccharine sodique 0,01Saccharin sodium 0.01
Colorant CI. 16255 (E 124) 0,0025CI dye. 16255 (E 124) 0.0025
Eau purifiée QSP 100QSP 100 purified water
Gel crème anti-cellulite (%)Anti-cellulite cream gel (%)
Eau QSP 100Water QSP 100
Cyclométhicone 5,40Cyclomethicone 5.40
Octyl Palmitate 5,00Octyl Palmitate 5.00
Glycérides de Coco Hydrogénées 3,00Hydrogenated Coconut Glycerides 3.00
Alcool Béhénylique d'Arachide 2,55Peanut Behenyl Alcohol 2.55
Propylène Glycol 2,50Propylene Glycol 2.50
Isodécyl Néopentanoate 2,00Isodecyl Neopentanoate 2.00
Stéarate de Glycérylee 1,70Glyceryl Stearate 1.70
Alcool Cétylique 1,30Cetyl alcohol 1.30
Acide Stéarique 1,00Stearic Acid 1.00
PEG-6 1,00PEG-6 1.00
Cire d'abeille 0,40Beeswax 0,40
C13-14 Isoparafine 0,40 Butylène Glycol 0,16C13-14 Isoparafine 0.40 Butylene Glycol 0.16
Glycérine 0,16Glycerin 0,16
Alcool Cétéarylique 0,10Cetearyl alcohol 0.10
Cetyl Palmitate 0,10 Cocoglycérides 0,10Cetyl Palmitate 0.10 Cocoglycerides 0.10
Laureth-7 0,10Laureth-7 0.10
4,5,7-Trihydroxyisoflavone 0,01 à 104,5,7-Trihydroxyisoflavone 0.01 to 10
Extrait de Enteromorpha Compressa 0,01 à 5Enteromorpha Compressa extract 0.01 to 5
Extrait de Sophora Japonica 0,01 à 20 Extrait de Centella Asiatica 0,01 à 5Sophora Japonica extract 0.01 to 20 Centella Asiatica extract 0.01 to 5
Extrait de Momordica charantia 0,01 à 10 Conservateur QS ParfumQSMomordica charantia extract 0.01 to 10 Preservative QS ParfumQS
Exemple 2 : formulations cosmétiques à base d'un extrait de grenadierExample 2 Cosmetic Formulations Based on a Pomegranate Extract
Crème anti acnéAcne cream
Eau QSP 100%Water QSP 100%
Isononyl Isononanoate 7,000 Di-C12-13 Alkyl Malate 7,000Isononyl Isononanoate 7,000 Di-C 12-13 Alkyl Malate 7,000
Stéarate isocétyle 5,000Isocetyl stearate 5,000
Butylène Glycol 3,000Butylene Glycol 3,000
Oriza Sativa 2,500Oriza Sativa 2,500
Extrait de grenadier 2,000 Dicaprylyl Ether 2,000Pomegranate Extract 2,000 Dicaprylyl Ether 2,000
Salicylate de silanediol 2,000Silanediol salicylate 2,000
Alcool arachique 1,650Arachic alcohol 1,650
Trométhamine 1,180Tromethamine 1,180
Alcool cétylique 1 ,000 Acide salicylique 1,000Cetyl alcohol 1, 000 Salicylic acid 1,000
Glucoside Ascorbyl 1,000Glucoside Ascorbyl 1,000
Glycine 1,000 Acétate de Tocopheryl 1,000Glycine 1,000 Tocopheryl acetate 1,000
Alcool béhénylique 0,900Behenyl alcohol 0.900
Squalane 0,790Squalane 0.790
Citrate de sodium 0,660Sodium citrate 0.660
Copolymère PPG-12/SMDI 0,500PPG-12 / SMDI Copolymer 0.500
Glucoside Arachidyl 0,4500.450 Arachidyl Glucoside
Parfum 0,400Perfume 0.400
Gomme Sclerotium 0,160Gum Sclerotium 0.160
Alcool cétéarylique 0,130Cetearyl alcohol 0.130
Acide citrique 0,110Citric acid 0.110
Sepigel 305* 0,100Sepigel 305 * 0.100
Système conservateur QSConservative QS system
*produit commercialisé par la société Seppic* product marketed by the company Seppic
QSP : Quantité Suffisante Pour ; QS : Quantité SuffisanteQSP: Sufficient Quantity For; QS: Sufficient quantity
Bain de boucheMouthwash
Extrait de grenadier 0,1 à 10%Pomegranate extract 0.1 to 10%
Alcool éthylique 10Ethyl alcohol 10
Glycérine 10Glycerin 10
Huile de ricin hydrogénée,Hydrogenated castor oil,
Ethoxylée à 40 moles EO 0,5Ethoxylated at 40 moles EO 0.5
(Crémophor co410)(Cremophor co410)
Poly(Methyl vinyl ether/ Acide Maléïque) 0,2Poly (Methyl vinyl ether / maleic acid) 0.2
(Gantrez S97BF)(Gantrez S97BF)
Soude 0,15Soda 0.15
Fluorure de sodium 0,050.05 sodium fluoride
Arôme Cannelle-Menthe 0,1Cinnamon-Mint aroma 0,1
Triclosan 0,03Triclosan 0.03
Chlorure de zinc 0,010.01 zinc chloride
Saccharine sodique 0,01Saccharin sodium 0.01
Colorant CI. 16255 (E 124) 0,0025CI dye. 16255 (E 124) 0.0025
Eau purifiée QSP 100 Gel crème anti-cellulite (%)QSP 100 purified water Anti-cellulite cream gel (%)
Eau QSP 100Water QSP 100
Cyclométhicone 5,40 Octyl Palmitate 5,00Cyclomethicone 5.40 Octyl Palmitate 5.00
Glycérides de Coco Hydrogénées 3,00Hydrogenated Coconut Glycerides 3.00
Alcool Béhénylique d'Arachide 2,55Peanut Behenyl Alcohol 2.55
Propylène Glycol 2,50Propylene Glycol 2.50
Isodécyl Néopentanoate 2,00 Stéarate de Glycérylee 1,70Isodecyl Neopentanoate 2.00 Glyceryl Stearate 1.70
Alcool Cétylique 1,30Cetyl alcohol 1.30
Acide Stéarique 1,00Stearic Acid 1.00
PEG-6 1,00PEG-6 1.00
Cire d'abeille 0,40 C13-14 Isoparafine 0,40Beeswax 0,40 C13-14 Isoparafine 0,40
Butylène Glycol 0,16Butylene Glycol 0.16
Glycérine 0,16Glycerin 0,16
Alcool Cétéarylique 0,10Cetearyl alcohol 0.10
Cetyl Palmitate 0,10 Cocoglycérides 0,10Cetyl Palmitate 0.10 Cocoglycerides 0.10
Laureth-7 0,10Laureth-7 0.10
4,5,7-Trihydroxyisoflavone 0,01 à 104,5,7-Trihydroxyisoflavone 0.01 to 10
Extrait de Enteromorpha Compressa 0,01 à 5Enteromorpha Compressa extract 0.01 to 5
Extrait de Sophora Japonica 0,01 à 20 Extrait de Centella Asiatica 0,01 à 5Sophora Japonica extract 0.01 to 20 Centella Asiatica extract 0.01 to 5
Extrait de grenadier 0,01 à 10Pomegranate extract 0.01 to 10
Conservateur QS ParfumQS Exemple 3 : formulations cosmétiques à base d'un extrait de calendulaConservative QS ParfumQS Example 3 Cosmetic Formulations Based on a Calendula Extract
Crème anti acnéAcne cream
Eau QSP 100%Water QSP 100%
Isononyl Isononanoate 7,000Isononyl Isononanoate 7,000
Di-C12-13 Alkyl Malate 7,000Di-C 12-13 Alkyl Malate 7,000
Stéarate isocétyle 5,000Isocetyl stearate 5,000
Butylène Glycol 3,000Butylene Glycol 3,000
Oriza Sativa 2,500Oriza Sativa 2,500
Extrait de calendula 2,000Calendula extract 2,000
Dicaprylyl Ether 2,000Dicaprylyl Ether 2,000
Salicylate de silanediol 2,000Silanediol salicylate 2,000
Alcool arachique 1,650Arachic alcohol 1,650
Trométhamine 1,180Tromethamine 1,180
Alcool cétylique 1,000Cetyl alcohol 1,000
Acide salicylique 1,000Salicylic acid 1,000
Glucoside Ascorbyl 1,000Glucoside Ascorbyl 1,000
Glycine 1,000Glycine 1,000
Acétate de Tocopheryl 1,000Tocopheryl acetate 1,000
Alcool béhénylique 0,900Behenyl alcohol 0.900
Squalane 0,790Squalane 0.790
Citrate de sodium 0,660Sodium citrate 0.660
Copolymère PPG-12/SMDI 0,500PPG-12 / SMDI Copolymer 0.500
Glucoside Arachidyl 0,4500.450 Arachidyl Glucoside
Parfum 0,400Perfume 0.400
Gomme Sclerotium 0,160Gum Sclerotium 0.160
Alcool cétéarylique 0,130Cetearyl alcohol 0.130
Acide citrique 0,110Citric acid 0.110
Sepigel 305* 0,100Sepigel 305 * 0.100
Système conservateur QS ^produit commercialisé par la société SeppicConservative System QS ^ product marketed by the company Seppic
QSP : Quantité Suffisante Pour ; QS : Quantité Suffisante Bain de boucheQSP: Sufficient Quantity For; QS: Sufficient quantity Mouthwash
Extrait de calendula 0,1 à 10%0.1 to 10% calendula extract
Alcool éthylique 10Ethyl alcohol 10
Glycérine 10Glycerin 10
Huile de ricin hydrogénée,Hydrogenated castor oil,
Ethoxylée à 40 moles EO 0,5Ethoxylated at 40 moles EO 0.5
(Crémophor co410)(Cremophor co410)
Poly(Methyl vinyl ether/ Acide Maléïque) 0,2Poly (Methyl vinyl ether / maleic acid) 0.2
(Gantrez S97BF)(Gantrez S97BF)
Soude 0,15Soda 0.15
Fluorure de sodium 0,050.05 sodium fluoride
Arôme Cannelle-Menthe 0,1Cinnamon-Mint aroma 0,1
Triclosan 0,03Triclosan 0.03
Chlorure de zinc 0,010.01 zinc chloride
Saccharine sodique 0,01Saccharin sodium 0.01
Colorant CI. 16255 (E 124) 0,0025CI dye. 16255 (E 124) 0.0025
Eau purifiée QSPlOOQSPlOO purified water
Gel crème anti-cellulite (%)Anti-cellulite cream gel (%)
Eau QSP 100Water QSP 100
Cyclométhicone 5,40Cyclomethicone 5.40
Octyl Palmitate 5,00Octyl Palmitate 5.00
Glycérides de Coco Hydrogénées 3,00Hydrogenated Coconut Glycerides 3.00
Alcool Béhénylique d'Arachide 2,55Peanut Behenyl Alcohol 2.55
Propylène Glycol 2,50Propylene Glycol 2.50
Isodécyl Néopentanoate 2,00Isodecyl Neopentanoate 2.00
Stéarate de Glycérylee 1,70Glyceryl Stearate 1.70
Alcool Cétylique 1,30Cetyl alcohol 1.30
Acide Stéarique 1,00Stearic Acid 1.00
PEG-6 1,00PEG-6 1.00
Cire d'abeille 0,40Beeswax 0,40
Cl 3- 14 Isoparafme 0,40 Butylène Glycol 0,16Cl 3- 14 Isoparafm 0.40 Butylene Glycol 0.16
Glycérine 0,16Glycerin 0,16
Alcool Cétéarylique 0,10Cetearyl alcohol 0.10
Cetyl Palmitate 0,10 Cocoglycérides 0,10Cetyl Palmitate 0.10 Cocoglycerides 0.10
Laureth-7 0,10Laureth-7 0.10
4,5,7-Trihydroxyisoflavone 0,01 à 104,5,7-Trihydroxyisoflavone 0.01 to 10
Extrait de Enteromorpha Compressa 0,01 à 5Enteromorpha Compressa extract 0.01 to 5
Extrait de Sophora Japonica 0,01 à 20 Extrait de Centella Asiatica 0,01 à 5Sophora Japonica extract 0.01 to 20 Centella Asiatica extract 0.01 to 5
Extrait de calendula 0,01 à 10Calendula extract 0.01 to 10
Conservateur QSConservative QS
Parfum QSPerfume QS
Exemple 4 : Etude de l'effet d'un extrait de Momordica charantia dans un modèle d'inflammation cutanée induite mécaniquement (rasage) chez la souris sauvage Balb/c. ProtocoleExample 4: Study of the effect of an extract of Momordica charantia in a model of mechanically induced cutaneous inflammation (shaving) in the wild Balb / c mouse. Protocol
L'étude a été réalisée sur des souris Balb/c femelles âgées de 6 semaines. Chaque groupe de souris est constitué de 8 souris. A JO, les souris sont rasées sur le dosThe study was performed on female Balb / c mice aged 6 weeks. Each group of mice consists of 8 mice. At OJ, the mice are shaved on their backs
(surface d'environ 2 cm2). A J2, un premier groupe de souris est utilisé pour obtenir les valeurs de base. L'application topique d'un extrait as Momordica charantia, en solution dans un mélange acétone/huile d'olive (ratio 4/1), commence à J2. L'extrait de(surface of about 2 cm 2 ). At J2, a first group of mice is used to obtain the basic values. The topical application of Momordica charantia extract, in solution in acetone / olive oil (ratio 4/1), begins on D2. The extract of
Momordica charantia est appliqué à la dose de 2%, à raison de deux applications par jour. A J4, c'est à dire après 2 jours d'application topique d'extrait de Momordica charantia, des biopsies de peau sont réalisées. Une analyse histologique est réalisée par coloration des coupes à Phématoxyline/éosine.Momordica charantia is applied at a dose of 2%, twice daily. At day 4, ie after 2 days of topical application of Momordica charantia extract, skin biopsies are performed. Histological analysis is performed by staining the haematoxylin / eosin sections.
L'extrait de Momordica charantia utilisé comprend en poids :The extract of Momordica charantia used includes by weight:
- insaponifiables 0,9 % en poids - stéarique 33,3 % en poids- unsaponifiables 0.9% by weight - stearic 33.3% by weight
- acide oléïque 3,2 % en poids- oleic acid 3.2% by weight
- acide linoléique 4,3 % en poids - acide linolénique >0,l % en poids- linoleic acid 4.3% by weight linolenic acid> 0.1% by weight
- acide catalpique et/ou alpha-éléostéarique 49,1 % en poids RésultatsCatalpic acid and / or alpha-eleostearic acid 49.1% by weight
A J4, les animaux présentent des signes d'inflammation au niveau du site de rasage, qui sont quantifiés via la mesure de l'épaisseur de la peau. En effet, une augmentation de l'épaisseur de la peau est corrélée avec l'inflammation. Le groupe traité par le véhicule (acétone/huile d'olive) présente à J4, une épaisseur de la peau, statistiquement supérieure à celle du groupe traité avec 2% d'extrait de Momordica charantia pendant 2 jours (Figure 1). En d'autres termes, on a montré, de façon tout à fait inattendue, qu'un extrait de Momordica charantia présente des propriétés anti¬ inflammatoires dans un modèle d'inflammation cutanée induite mécaniquement chez la souris. Les résultats sont résumés sur la figure 1 ci-jointe, qui représente en ordonnée l'épaisseur de la peau, en microns à J4, mesurée dans chacun des groupes traités (véhicule : acétone/huile d'olive ou extrait de Momordica charantia).On day 4, the animals show signs of inflammation at the shaving site, which are quantified by measuring the thickness of the skin. Indeed, an increase in the thickness of the skin is correlated with the inflammation. The vehicle-treated group (acetone / olive oil) has a skin thickness at J4, statistically higher than that of the group treated with 2% Momordica charantia extract for 2 days (Figure 1). In other words, it has been shown, quite unexpectedly, that an extract of Momordica charantia has anti-inflammatory properties in a mechanically induced skin inflammation model in mice. The results are summarized in the attached FIG. 1, which represents, on the ordinate, the thickness of the skin, in microns at day 4, measured in each of the treated groups (vehicle: acetone / olive oil or Momordica charantia extract).
Exemple 5 ; Etude de l'effet d'un extrait de Momordica charantia, appliqué en topique à la dose de 2% chez la souris sauvage Balb/c, sur la prolifération des kératinocytes. Protocole L'étude a été réalisée sur des souris Balb/c femelles âgées de 6 semaines.Example 5; Study of the effect of an extract of Momordica charantia, applied topically at the dose of 2% in the Balb / c wild-type mouse, on the proliferation of keratinocytes. Protocol The study was performed on female Balb / c mice aged 6 weeks.
Chaque groupe de souris est constitué de 8 souris. A JO, les souris sont rasées sur le dos (surface d'environ 2 cm2). A J2, un premier groupe de souris est utilisé pour obtenir les valeurs de base. L'application topique d'un extrait de Momordica charantia, en solution dans un mélange acétone/huile d'olive (ratio 4/1), commence à J2. L'extrait de Momordica charantia est appliqué à la dose de 2% pendant 30 jours, à raison de deux applications par jour. L'extrait de Momordica charantia utilisé est le même que celui de l'exemple 4.Each group of mice consists of 8 mice. At OJ, the mice are shaved on the back (surface of about 2 cm 2 ). At J2, a first group of mice is used to obtain the basic values. The topical application of an extract of Momordica charantia, dissolved in an acetone / olive oil mixture (ratio 4/1), begins on D2. Momordica charantia extract is applied at 2% for 30 days, twice daily. The extract of Momordica charantia used is the same as that of Example 4.
Après 4 semaines d'application, des biopsies de peau sont réalisées et analysées par immuno-histochimie avec un anti-corps anti-Ki67 (marqueur de prolifération). 5 mesures différentes seront effectuées pour chacune des souris. RésultatsAfter 4 weeks of application, skin biopsies are performed and analyzed by immunohistochemistry with anti-Ki67 antibody (proliferation marker). 5 different measurements will be made for each of the mice. Results
Comme le montre la figure ci-jointe, l'application topique d'un extrait de Momordica charantia à la dose de 2% (pendant 4 semaines, à raison de deux applications par jour), entraîne une augmentation statistiquement significative du pourcentage de cellules Ki-67 positives par rapport au véhicule seul.As shown in the attached figure, topical application of Momordica charantia extract at a dose of 2% (for 4 weeks at two applications per day) results in a statistically significant increase in the percentage of Ki cells. -67 positive compared to the vehicle alone.
La figure 2 ci-jointe représente en ordonnée le pourcentage de cellules Ki-67 positives par rapport au nombre total de cellules mesuré à J30 dans chacun des groupes traités (véhicule : acétone/huile d'olive ou extrait de Momordica charantia).The attached FIG. 2 represents the percentage of Ki-67 positive cells relative to the total number of cells measured at J30 in each of the treated groups (vehicle: acetone / olive oil or Momordica charantia extract).
On montre ainsi que de façon tout à fait surprenante un extrait de Momordica charantia entraîne une augmentation de la prolifération des kératinocytes in vivo chez la souris. En d'autres termes, l'extrait de Momordica charantia présente des propriétés cicatrisantes, et eutrophiques. Les dites propriétés eutrophiques sont avantageuses notamment dans le cadre de pathologies cutanées caractérisées par un trouble de la barrière cutanée.It is thus shown that, quite surprisingly, an extract of Momordica charantia causes an increase in the proliferation of keratinocytes in vivo in the mouse. In other words, Momordica charantia extract has healing and eutrophic properties. The said eutrophic properties are advantageous especially in the context of cutaneous pathologies characterized by a skin barrier disorder.
Exemple 6 : Evaluation de la synthèse lipidique dans des adipocytes en suspensionExample 6 Evaluation of Lipid Synthesis in Suspended Adipocytes
Produit à l'essaiProduct tested
L'extrait de Momordica charantia utilisé est le même que celui de l'exemple 4. Conditions de cultureThe extract of Momordica charantia used is the same as that of Example 4. Culture conditions
Des adipocytes humains normaux ont été isolés à partir de biopsies abdominalesNormal human adipocytes were isolated from abdominal biopsies
(chirurgie plastique). Immédiatement après la réception, les prélèvements sont incubés pendant 30 min à 37°C en présence de collagénase (Sigma). La suspension d'adipocytes est ensuite rincée et diluée 3 fois dans le milieu de culture. Milieu de culture : bicarbonate (Life Technologies) 1,87 mg/ml, pénicilline/streptomycine (Life Technologies) 25 Ul/ml/ 25μg/ml, glutamine (Life(plastic surgery). Immediately after reception, the samples are incubated for 30 min at 37 ° C in the presence of collagenase (Sigma). The adipocyte suspension is then rinsed and diluted 3 times in the culture medium. Culture medium: bicarbonate (Life Technologies) 1.87 mg / ml, penicillin / streptomycin (Life Technologies) 25 IU / ml / 25μg / ml, glutamine (Life
Technologies) 2 mM, MEM (Merck Eurolab) 100% v/v, albumine d'origine bovineTechnologies) 2mM, MEM (Merck Eurolab) 100% v / v, albumin of bovine origin
(Sigma) 0,5% p/v.(Sigma) 0.5% w / v.
Evaluation de la synthèse lipidique Les adipocytes en suspension sont incubés pendant Ih à 370C en présence de différentes concentrations de MAI 05 (20 et 2 ppm) dilué dans du THFEvaluation of lipid synthesis The suspended adipocytes are incubated for 1 h at 37 ° C. in the presence of different concentrations of MAI 05 (20 and 2 ppm) diluted in THF
(tétrahydrofurane). Un volume de 10 ml d'acétate radio-marqué (2-C14, 60,87 μCi/ml, Amersham) est ensuite ajouté à la préparation. Après 4h d'incubation, les lipides sont extraits selon la procédure décrite par Bligh et Dyer (méthanol/chloroforme/eau), évaporés sous azote et la radio-activité incorporée a été quantifiée par scintillation liquide (LKB 1210 Rackbeta). Résultats(Tetrahydrofuran). A volume of 10 ml of radio-labeled acetate (2-C 14 , 60.87 μCi / ml, Amersham) is then added to the preparation. After 4 hours of incubation, the lipids are extracted according to the procedure described by Bligh and Dyer (methanol / chloroform / water), evaporated under nitrogen and the incorporated radioactivity was quantified by liquid scintillation (LKB 1210 Rackbeta). Results
L'extrait de Momordica charantia n'induit aucune interférence avec le radio- marquage. La molécule de référence, la céruline (inhibiteur de FAS, Fatty Acid Synthase) testée à 10 μM inhibe l'incorporation d'acétate (75% d'inhibition/témoin). Ce résultat valide l'essai. L'extrait de Momordica charantia testé à 2 et 20 ppm diminue significativement l'incorporation d'acétate dans les lipides (respectivement 25 et 30% du témoin). L'extrait de Momordica charantia montre une activité inhibitrice significative de la synthèse des lipides. L'extrait de Momordica charantia est donc capable d'inhiber la lipogenèse dans des adipocytes humains en culture. Cette expérience montre de manière tout à fait inattendue l'intérêt du produit dans la prise en charge de la cellulite.Momordica charantia extract does not induce any interference with radiolabeling. The reference molecule, cerulin (FAS inhibitor, Fatty Acid Synthase) tested at 10 μM inhibits the incorporation of acetate (75% inhibition / control). This result validates the test. The extract of Momordica charantia tested at 2 and 20 ppm significantly reduces the incorporation of acetate into the lipids (respectively 25 and 30% of the control). Momordica charantia extract shows a significant inhibitory activity of lipid synthesis. The extract of Momordica charantia is therefore capable of inhibiting lipogenesis in human adipocytes in culture. This experience shows quite unexpectedly the interest of the product in the management of cellulite.
La figure 3 ci-joint illustre l'effet de l'extrait de Momordica charantia sur l'incorporation d'acétate radio-marqué dans les lipides adipocytaires. Les résultats sont significatifs (p<0,01). Figure 3 attached illustrates the effect of Momordica charantia extract on the incorporation of radiolabelled acetate into adipocyte lipids. The results are significant (p <0.01).

Claims

REVENDICATIONS
1. Utilisation d'une composition comprenant au moins un acide gras choisi dans le groupe constitué par l'acide alpha-éléostéarique, l'acide catalpique, l'acide calendique, l'acide jacarique, l'acide licanique et l'acide béta-éléostéarique, pour la fabrication d'un médicament destiné à la prévention et/ou au traitement des maladies inflammatoires et/ou des désordres métaboliques consécutifs à une inflammation de la peau, des muqueuses et/ou des cartilages.1. Use of a composition comprising at least one fatty acid selected from the group consisting of alpha-eleostearic acid, catalpic acid, calendrical acid, jacaric acid, licanic acid and beta-acid -eleostearic acid, for the manufacture of a medicament for the prevention and / or treatment of inflammatory diseases and / or metabolic disorders resulting from inflammation of the skin, mucous membranes and / or cartilage.
2. Utilisation selon la revendication 1, caractérisée en ce que l'inflammation est due aux rayonnements solaires, à des radiations ionisantes, aux infra rouges, à la chaleur ou au froid.2. Use according to claim 1, characterized in that the ignition is due to solar radiation, ionizing radiation, infrared, heat or cold.
3. Utilisation selon la revendication 2, caractérisée en ce que le médicament est destiné à la prévention et/ou au traitement des maladies choisies dans le groupe constitué par les cancers cutanés, Pérythème solaire et la lucite estivale bénigne, lesdits cancers cutanés étant en particulier choisis dans le groupe constitué par les cancers basocellulaire et spinocellulaire ou le mélanome malin.3. Use according to claim 2, characterized in that the drug is intended for the prevention and / or treatment of diseases selected from the group consisting of skin cancers, solar perythema and benign summer lucitis, said skin cancers being in particular selected from the group consisting of basal cell and squamous cell carcinoma or malignant melanoma.
4. Utilisation selon la revendication 1, caractérisée en ce que le médicament est destiné à la prévention et/ou au traitement des réactions allergiques et/ou irritatives de la peau et/ou des muqueuses.4. Use according to claim 1, characterized in that the drug is intended for the prevention and / or treatment of allergic and / or irritative reactions of the skin and / or mucous membranes.
5. Utilisation selon la revendication 1, caractérisée en ce que le médicament est également destiné à favoriser la cicatrisation.5. Use according to claim 1, characterized in that the medicament is also intended to promote healing.
6. Utilisation selon la revendication 4 ou 5, caractérisée en ce que le médicament est destiné à la prévention et/ou au traitement des maladies choisies dans le groupe constitué par l'eczéma atopique, les dermatoses inflammatoires telles que le psoriasis, les dermites irritatives, l'acné, la dermite séborrhéique, l'eczéma nummulaire, l'eczéma dyshidrosique, le Pytiriasis alba, l'eczéma craquelé, les eczéma nutritionnels, l'urticaire, les dermatoses parasitaires, les dermatoses virales, les dermatoses fongiques ou bactériennes, Pintertrigo, les troubles de la vascularisation topique inflammatoires, l'ulcère du pied et/ou les piqûres d'insectes.6. Use according to claim 4 or 5, characterized in that the drug is intended for the prevention and / or treatment of diseases selected from the group consisting of atopic eczema, inflammatory dermatoses such as psoriasis, irritative dermatitis. , acne, seborrheic dermatitis, nummular eczema, dyshidrotic eczema, Pytiriasis alba, cracked eczema, eczema nutritional, urticaria, parasitic dermatoses, viral dermatoses, fungal dermatoses or bacterial, intertrigo, inflammatory topical vascularization disorders, foot ulcer and / or insect bites.
7. Utilisation selon la revendication 1, caractérisée en ce que le médicament est destiné à la prévention et/ou au traitement des maladies choisies dans le groupe constitué par les gingivites et les parodontites.7. Use according to claim 1, characterized in that the drug is intended for the prevention and / or treatment of diseases selected from the group consisting of gingivitis and periodontitis.
8. Utilisation selon la revendication 1, caractérisée en ce que le médicament est destiné à la prévention et/ou au traitement des maladies choisies dans le groupe constitué par les vulvites et les vaginites.8. Use according to claim 1, characterized in that the drug is intended for the prevention and / or treatment of diseases selected from the group consisting of vulvitis and vaginitis.
9. Utilisation selon la revendication 1, caractérisée en ce que le médicament est destiné à la prévention et/ou au traitement des maladies choisies dans le groupe constitué par l'arthrite et l'arthrose.9. Use according to claim 1, characterized in that the drug is intended for the prevention and / or treatment of diseases selected from the group consisting of arthritis and osteoarthritis.
10. Utilisation d'une composition comprenant au moins un acide gras choisi dans le groupe constitué par l'acide alpha-éléostéarique, l'acide catalpique, l'acide calendique, l'acide jacarique, l'acide licanique et l'acide béta-éléostéarique, pour le traitement cosmétique des peaux et/ou des muqueuses sensibles, irritées, intolérantes, à tendance allergique, âgées, présentant un trouble de la barrière cutanée, présentant des rougeurs cutanées ou présentant un déséquilibre imrnunologique non pathologique lié au vieillissement intrinsèque, extrinsèque ou hormonal.Use of a composition comprising at least one fatty acid selected from the group consisting of alpha-eleostearic acid, catalpic acid, calendrical acid, jacaric acid, licanic acid and beta acid -eleostearic, for the cosmetic treatment of skins and / or mucous membranes sensitive, irritated, intolerant, with an allergic tendency, aged, presenting a skin barrier disorder, having cutaneous redness or having a non-pathological immunological imbalance related to intrinsic aging, extrinsic or hormonal.
11. Utilisation d'une composition comprenant au moins un acide gras conjugué choisi dans le groupe constitué par l'acide alpha-éléostéarique, l'acide catalpique, l'acide calendique, l'acide jacarique, l'acide licanique et l'acide béta-éléostéarique, pour le traitement cosmétique de la cellulite.11. Use of a composition comprising at least one conjugated fatty acid selected from the group consisting of alpha-eleostearic acid, catalpic acid, calendrical acid, jacaric acid, licanic acid and acid beta-eleostearic, for the cosmetic treatment of cellulite.
12. Utilisation selon l'une quelconque des revendications 1 à 11, caractérisée en ce que la composition est administrée par voie topique ou orale. 12. Use according to any one of claims 1 to 11, characterized in that the composition is administered topically or orally.
13. Utilisation selon la revendication 12, caractérisée en ce que la composition administrée par voie topique comprend 0,001 à 50% en poids, avantageusement 0,5 à 20% en poids, d'acide alpha-éléostéarique, par rapport au poids total de ladite composition13. Use according to claim 12, characterized in that the composition administered topically comprises 0.001 to 50% by weight, preferably 0.5 to 20% by weight, of alpha-eleostearic acid, relative to the total weight of said composition
14. Utilisation selon la revendication 12 ou 15, caractérisée en ce que la composition administrée par voie topique comprend 0,001 à 50% en poids, avantageusement 0,5 à 20% en poids, d'acide alpha-éléostéarique et 0,001 à 50% en poids, avantageusement 0,5 à 20% en poids, d'acide catalpique, par rapport au poids total de ladite composition.14. Use according to claim 12 or 15, characterized in that the composition administered topically comprises 0.001 to 50% by weight, advantageously 0.5 to 20% by weight, alpha-eleostearic acid and 0.001 to 50% by weight. weight, advantageously 0.5 to 20% by weight, of catalpic acid, relative to the total weight of said composition.
15. Utilisation selon la revendication 12, caractérisée en ce que la composition administrée par voie orale comprend 0,001 à 100% en poids, avantageusement 1 à 50% en poids, d'acide alpha-éléostéarique, par rapport au poids total de ladite composition15. Use according to claim 12, characterized in that the composition administered orally comprises 0.001 to 100% by weight, preferably 1 to 50% by weight, of alpha-eleostearic acid, relative to the total weight of said composition.
16. Utilisation selon la revendication 12 ou 15, caractérisée en ce que la composition administrée par voie orale comprend 0,001 à 100% en poids, avantageusement 1 à 50% en poids, d'acide alpha-éléostéarique et 0,001 à 100% en poids, avantageusement 1 à 50% en poids, d'acide catalpique, par rapport au poids total de ladite composition.16. Use according to claim 12 or 15, characterized in that the orally administered composition comprises 0.001 to 100% by weight, preferably 1 to 50% by weight, alpha-eleostearic acid and 0.001 to 100% by weight, advantageously 1 to 50% by weight of catalpic acid, relative to the total weight of said composition.
17. Utilisation selon l'une quelconque des revendications 1 à 16, caractérisée en ce que la composition comprend en association des principes actifs choisis dans le groupe constitué par les agents anti-inflammatoires.17. Use according to any one of claims 1 to 16, characterized in that the composition comprises in combination active ingredients selected from the group consisting of anti-inflammatory agents.
18. Utilisation selon l'une quelconque des revendications 1 à 17, caractérisée en ce que la source acide gras conjugué est un extrait lipidique d'au moins un végétal choisi dans le groupe constitué par les végétaux de la famille des Cucurbitaceés, des Punicacées, des Bignoniacées, des Euphorbiacées, des Compositées (Asteracées), des Balsaminacées, des Rosacées, des Chrysobalanacées, des Ricinocarpus et des Chilopsis.18. Use according to any one of claims 1 to 17, characterized in that the conjugated fatty acid source is a lipid extract of at least one plant selected from the group consisting of plants of the family Cucurbitaceae, Punicaceae, Bignoniaceae, Euphorbiaceae, Composites (Asteraceae), Balsaminaceae, Rosaceae, Chrysobalanaceae, Ricinocarpus and Chilopsis.
19. Utilisation selon la revendication 18, caractérisée en ce que la source acide gras conjugué est un extrait lipidique d'au moins un végétal choisi dans le groupe constitué par les Mormordica verts, blancs, perlés, et sauvage, le Catalpa, l'Aleurites, l'Euphorbe, le Parinarium, le Licania, le Parinarium le Calendula, le Punica, le grenadier, le bois de chine, le balsam, le Trichosanthès, le Centratus et le Jacaranda .19. Use according to claim 18, characterized in that the conjugated fatty acid source is a lipid extract of at least one plant selected from the group consisting of green, white, pearled, and wild Mormordica, Catalpa, Aleurites , the Euphorbia, Parinarium, Licania, Parinarium Calendula, Punica, Pomegranate, Chinese Wood, Balsam, Trichosanthus, Centratus and Jacaranda.
20. Utilisation selon la revendication 19, caractérisée en ce que la source d'acide alpha-éléostéarique et d'acide catalpique est un extrait lipidique de graines de20. Use according to claim 19, characterized in that the source of alpha-eleostearic acid and catalpic acid is a lipid extract of seeds of
Moraiordica, avantageusement de graines de Momordica charantia.Moraiordica, advantageously of seeds of Momordica charantia.
21. Utilisation selon la revendication 20, caractérisée en ce que l'extrait lipidique de Momordica est susceptible d'être obtenu par un procédé consistant à extraire les lipides totaux des graines de Momordica préalablement séchées et broyées, à l'aide d'un solvant des huiles, puis à évaporer ledit solvant ou selon le procédé consistant à extraire les lipides des graines de Momordica par pression mécanique des graines à froid. 21. Use according to claim 20, characterized in that the lipid extract of Momordica is obtainable by a process consisting in extracting the total lipids of Momordica seeds which have been dried and ground beforehand, using a solvent. oils, and then evaporating said solvent or by the process of extracting the lipids from the Momordica seeds by mechanical pressure of the seeds cold.
EP05790724A 2004-07-26 2005-07-20 Use of at least one conjugated triene-containing fatty acid for preparing a medicine for treating inflammation Withdrawn EP1786384A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0408230A FR2873295B1 (en) 2004-07-26 2004-07-26 USE OF AT LEAST ONE CONJUGATED FATTY ACID TRIENE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF INFLAMMATION
PCT/FR2005/001859 WO2006021660A1 (en) 2004-07-26 2005-07-20 Use of at least one conjugated triene-containing fatty acid for preparing a medicine for treating inflammation

Publications (1)

Publication Number Publication Date
EP1786384A1 true EP1786384A1 (en) 2007-05-23

Family

ID=34949333

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05790724A Withdrawn EP1786384A1 (en) 2004-07-26 2005-07-20 Use of at least one conjugated triene-containing fatty acid for preparing a medicine for treating inflammation

Country Status (4)

Country Link
US (1) US20080045594A1 (en)
EP (1) EP1786384A1 (en)
FR (1) FR2873295B1 (en)
WO (1) WO2006021660A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009058799A1 (en) * 2007-11-01 2009-05-07 Wake Forest University School Of Medicine Compositions and methods for prevention and treatment of mammalian diseases
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
FR2929515B1 (en) * 2008-04-08 2014-03-07 Lr Beva USE OF FATTY ACIDS COMPRISING A CONJUGATED DIENE N-5CIS, N-7TRANS OR CONJUGATED TRIENE N-5CIS, N-7TRANS, N-9CIS AS A MEDICINAL PRODUCT
GB0814105D0 (en) * 2008-08-01 2008-09-10 Springdale Sustainable Develop Composition for accelerated production of collagen
AU2009306492B2 (en) 2008-10-24 2013-05-30 Unilever Plc A topical composition comprising extracts of A. indica and M. charantia or S. indicum
GB0902040D0 (en) * 2009-02-06 2009-03-11 Seeds Lp Composition for treatment of skin
FR2949044B1 (en) * 2009-08-12 2021-05-07 Expanscience Lab COMPOSITION INCLUDING A FRACTION OF THE UNSAPONIFIABLE
KR100985719B1 (en) 2009-09-15 2010-10-06 (주)지에프씨 Cosmetic composition comprising catalpa ovata and hibiscus syriacus extracts as an effective component
FR2984730A1 (en) * 2011-12-22 2013-06-28 Diverchim NEW ANTI-AGE AND DEPIGMENTING COSMETIC COMPOSITIONS
IT201700037319A1 (en) 2017-04-05 2018-10-05 Moss S P A NATURAL COMPOSITION FOR USE IN GYNECOLOGY
AU2018372151B2 (en) 2017-11-22 2023-11-09 Organicare, Llc Method for the production of an ozonized olive oil

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU616502B2 (en) * 1988-04-22 1991-10-31 Medvet Science Pty. Ltd. Treatment of inflammatory disorders in humans
FR2762512B1 (en) * 1997-04-24 2000-10-13 Pharmascience Lab LUPINE OIL COMPOSITIONS, ESPECIALLY BASED ON LUPINE OIL AND WHEAT GERM OIL AND THEIR USE IN COSMETOLOGY, PHARMACY AND AS A FOOD SUPPLEMENT
AU1293600A (en) * 1999-07-15 2001-02-05 Pushpa Khanna Oil from momordica charantia l., its method of preparation and uses
FR2798667B1 (en) * 1999-09-22 2001-12-21 Pharmascience Lab PROCESS FOR THE EXTRACTION OF FURANIC COMPOUNDS AND POLYHYDROXYL FATTY ALCOHOLS FROM LAWYER, COMPOSITION BASED ON AND USE OF THESE COMPOUNDS IN THERAPEUTICS, COSMETICS AND FOOD
CA2408357A1 (en) * 2000-05-09 2001-11-15 Bioriginal Food & Science Corp. Production of conjugated linoleic and linolenic acids in plants
WO2003000074A1 (en) * 2001-06-21 2003-01-03 Kyowa Hakko Kogyo Co., Ltd. Process for producing plant extract containing plant powder
FR2826579B1 (en) * 2001-06-29 2005-08-05 Pharmascience Lab COSMETIC COMPOSITION CONTAINING AT LEAST ONE OIL EXTRACTED FROM CUCURBITACEOUS SEEDS, ITS COSMETIC, THERAPEUTIC AND FOOD USE
DE10158046A1 (en) * 2001-11-27 2003-06-05 Basf Ag Formulation for use in food, food supplements, animal feed, feed additives, pharmaceutical and cosmetic preparations and processes for their preparation
JP2006518701A (en) * 2002-05-24 2006-08-17 ネオファーム、インコーポレイティッド Cardiolipin composition, process for its production and use
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006021660A1 *

Also Published As

Publication number Publication date
FR2873295B1 (en) 2006-12-01
FR2873295A1 (en) 2006-01-27
WO2006021660A1 (en) 2006-03-02
WO2006021660A8 (en) 2006-04-27
US20080045594A1 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
US11013699B2 (en) Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
EP1786384A1 (en) Use of at least one conjugated triene-containing fatty acid for preparing a medicine for treating inflammation
EP2654762B1 (en) Extract of the aerial parts of gynandropsis gynandra and cosmetic, dermatoligic and pharmaceutic compositions comprising the extract
CA2924382A1 (en) Lipid extract of passion fruit seeds
KR102156731B1 (en) Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
CA2911394A1 (en) Use of petroselinic acid to fight against aesthetic disorders of the body figure
US11918547B2 (en) Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
EP2811978B1 (en) Use of an apple tree bark extract in a cosmetic anti-ageing composition
WO2012172218A2 (en) Plant extract complex for skin protection
EP2811977B1 (en) Use of an apple tree leaf extract in a cosmetic skin-firming composition
EP2694028A2 (en) Composition based on chaulmoogra oil and tribulus terrestris for skin pigmentation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1103659

Country of ref document: HK

17Q First examination report despatched

Effective date: 20080310

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1103659

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150203